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In an attempt to establish a plant-based Human immunodeficiency virus-1 (HIV-1) 
subtype C neutralizing antibody stimulating vaccine, a Tobacco mosaic virus 
(TMV) derived vector was used to express recognized HIV neutralizing antibody 
epitopes. These epitopes were expressed on the surface of the TMV coat protein, 
which served as an ideal means of antigen display. This model antigen display 
system was capable of assembling into multivalent, highly repetitive structures 
thereby displaying many copies of the attached epitope in the assembled virion. 
Three TMV-based vectors were acquired, which were essentially identical, differing 
only in the position at which they could accommodate a foreign protein fusion. 
These vectors allowed the display of a foreign peptide at the N-terminus, C-
terminus or 60S-loop regions of the TMV coat protein. all of which protrude on the 
surface of the assembled virion. The HIV V3 loop is recognized as the principal 
neutralizing domain, and was the neutralizing epitopes displayed by the vectors. 
The epitope sequences used were derived from a cohort of infected individuals in 
Durban, South Africa, who displayed broad cross-neutralizing V3-specific activity 
towards heterologous viral strains. The recombinant viral vectors were shown to 
efficiently infect the host Nicotiana benthamiana plants and assemble into 
multivalent recombinant virion structures as observed by transmission electron 
microscopy. However, the level of coat protein expression was significantly 
dependent on the position of the coat protein fusion as either the levels of V3 
epitope expressed or TMV coat protein was found to vary between the different 











immunosorbent assays. Immunogenicity analysis using a guinea pig model was 
used to assess the ability of the recombinant vectors to firstly establish a V3-
specific immune response, and secondly to stimulate a virus-specific neutralization 
antibody response. As a result of time constraints only the C-terminal coat protein 
fusions were assessed in the guinea pig model. Inoculated guinea pigs displayed 
distinct and gradually increasing V3-specific immune responses after 2 boosts. 
Serum samples that displayed the strongest V3 peptide responses were then 
analyzed for their ability to neutralize HIV infection in HIV pseudovirion 
neutralization assays. Results for selected serum samples showed no HIV 
neutralizing activity above what could be recognized as background activity. Thus 
the candidate vaccine, although establishing a path for the assembly of a 
multivalent vaccine, failed in its attempt to stimulate a neutralizing antibody 
response. This study has nevertheless paved a direct path to the development of 
variations of this type of vaccine possibly using different and perhaps more 












AIDS acquired immunodeficiency syndrome 
AMV alfalfa mosaic virus 
bp base pair 
cDNA complementary deoxyribonucleic acid 
CP capsid protein 
CTL cytotoxic T -lymphocyte 
DNA deoxyribonucleic acid 
dpi days post inoculation 
ELISA enzyme-linked immunosorbent assay 
FCA Freund's complete adjuvant 
FIA Freund's incomplete adjuvant 
g gram 
HIV Human immunodeficiency virus 
HBsAg Hepatitis B surface antigen 
kDa kilo Dalton 
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In the present day, vaccines are considered to be an indispensable means of 
protection against an array of potentially lethal pathogens. Throughout recent 
history, they have provided an unsurpassed level of protection against several 
lethal diseases including smallpox and more recently, polio. 
In spite of the continued efforts in the battle against the Human immunodeficiency 
virus (HIV), infection remains rife and the epidemic continues to spread. Current 
statistics of HIV infection highlight the problem the medical world is faced with . As 
of the end of 2004 the estimated number of individuals living with HIV was 
approximately 40 million worldwide. Approximately two thirds of these people are 
located in sub-Saharan Africa. During 2004, an estimated 5 million new HIV 
infections occurred internationally. This translated to 14000 infections per day, 
95% of which occurred in developing countries (http://www.niaid .nih. 
gov/factsheets/aidsstat. htm). 
An untreated person will almost certainly fail to successfully combat an HIV 
infection, as infection is accompanied with an early immune dysfunction, which 
limits control of the virus. During HIV infection the virus is directed towards those 
cells of the immune system presenting CD4+ receptors at their surface (Popovic et 
aI., 1989; Zack et al., 1990; Dalgleish et al., 1991; Douek et aI., 2002; Lawson et 
a/., 2004; Oxenius et a/., 2004). Infection of these cells usually results in their lysis 
as a result of virus-induced and host immune system-induced consequences in 
response to infection, and a depletion of those cells required for the immune 











host's immune response is effectively crippled by the depletion of these cells. Most 
fatalities that arise from acquired immune deficiency syndrome (AIDS) are 
therefore a consequence of opportunistic infections, which are sufficient to kill the 
host due to the weakened immune system. An immune system which has been 
primed with an HIV vaccine however, would hopefully allow early recognition of the 
infecting virus and subsequent destruction of virus particles before they have an 
opportunity to become established within the host (Mascola et a/., 2000; Saba et 
a/., 2000; Letvin, 2002). 
As no effective HIV vaccine is currently present, drug therapy for the treatment of 
HIV-infected people is the alternative to vaccination. Currently several highly 
effective drugs exist such as protease inhibitors (ritonovir, saquinovir), nucleoside-
analogue reverse transcriptase inhibitors (AZT, lamivudine) and non-nucleoside 
reverse transcriptase inhibitors (nevirapine) (http://aegis.com/factshts/networkl 
simple/combo.html). The primary drawbacks of this form of therapy are that it is 
very expensive, has unpleasant side effects and its use is generally exclusive to 
those who can afford it. In spite of the vast amounts of research, no form of drug 
therapy has to date been demonstrated to cure an HIV infection. 
Vaccines have therefore been proposed as a means to prevent the virus from 
firmly establishing an infection within a previously uninfected person. Ideally, a 
vaccine directed against HIV should induce a neutralizing antibody (NAb) 
response, which would clear all detectable levels of HIV within the infected person 
(sterilizing immunity). Several such vaccine strategies have been tested but, 











remains elusive (http://aidsinfo.nih.gov/vaccinesl) . The development of an effective 
H IV vaccine is regarded as one of the most important future prospects with respect 
to vaccine design. In the ongoing battle against HIV, numerous potential vaccine 
strategies have reached pre-clinical and even clinical human trial levels 
(http://www.hvtn.org/science/trials.html). However, these studies have generally 
not generated encouraging results with regard to the development of a safe and 
effective vaccine and specific reference is made here to the recent HIV envelope 
protein based (AIDSVAX) phase III vaccine trials by VaxGen, which appeared to 
offer no significant protective efficacy (Adis International Ltd, 2003; Anonymous, 
2003). 
1.2 HIV ENVELOPE GL YCOPROTEINS 
HIV presents a 550 amino acid surface glycoprotein, gp120, at the exterior surface 
of the virion membrane (Figure. 1.1A) (Fields et aI., 1996). This surface 
glycoprotein is non-covalently associated with the transmembrane protein gp41 
(Figure. 1.18) and presents a binding domain for CD4 receptors found on the 
surface of T-Iymphocytes, monocytes, macrophages, mature 8-cells and dendritic 
cells. These gp120/41 associations form clusters of tri-molecular complexes on the 
virion membrane surface (Lu et aI., 1995; Chan et al., 1997; Farzan et aI., 1998). 
Gp120 interaction with target CD4 receptors and chemokine co-receptors 
(CCR5/CXCR4) plays an important role during virus infection by initiating the 
fusion of the virion membrane to the host cell membrane, and thus allowing entry 
of the virus into the host cell (Dalgleish et al., 1991; Deng et al. , 1996; Wyatt et al., 
1998 A). The HIV genome encodes the envelope glycoproteins as a single 160 











and 41 kDa (gp41) functional glycoproteins by the virus encoded protease. Thus 
during the membrane fusion process, if gp120 interaction with the CD4 receptors 
and chemokine co-receptors is considered as the initiation step in cellular infection, 
the activity of the gp41 transmembrane protein could be viewed as the functional 
unit that facilitates actual membrane fusion as follows (Chan et al., 1998): free 
virions are assumed to be in a native or non-fusogenic conformation, in which the 
gp41 fusion peptide that is inserted into the target membrane is buried inside the 
trimeric complex; upon the CD4 and chemokine receptor binding by gp120, 
structural rearrangement alters the gp120/41 interaction and triggers gp41 to 
undergo structural rearrangement. The exposure of the gp41 fusion peptide 
accompanies the structural rearrangement; it is then inserted into the target cell 
membrane, which causes further structural rearrangement within the gp41 trimeric-
coiled coil resulting in membrane apposition, which allows fusion of the virion and 
cell membranes. 
The gp120 amino acid sequence contains 18 highly conserved cysteine residues, 
which are assumed to play a critical role in the structural organisation and 
functionality of gp120 (Tschachler et al., 1990; Travis etal., 1992; Chiou et al., 
1992; Fields et al., 1996; Wyatt et al., 1998). Structural modelling has revealed that 
this protein is divided into several conformation-dependent regions, through the 
formation of disulphide bonds between cysteine residues. These are required for 
cellular receptor binding (CD 4) (Figure. 1.1 B) (Trkola et al., 1996; Fields et al., 
1996; Hoffman et al., 1999; Hung et al., 1999; Wang et al., 1999). Heterogeneity 
between individual HIV-1 isolates within gp120 has been localized to 5 variable 
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Figure. 1.1(A). Illustrates the position of the gp120 surface glycoproteins and gp41 
transmembrane proteins on the suface of an HIV virion (www.aegis.comltopics/ 
basics/hivandaids.html) ©1980, 2002. AEGiS. (8) Illustrates the tertiary structure of gp120 and 
displays the positioning of the variable loop structures (V1, V2, V3, V4, V5) (red arrows) as well 
as the non-covalent association with gp41 ( derived from Fields et al., 1996) 
1.2.1 Immunogenicity of HIV envelope glycoproteins 
Research has indicated that some antibodies directed towards envelope 
glycoproteins possess the ability to neutralize HIV infection (Weiss et al., 1986; 
Schwartz, et al., 1993; Muhlbacher et al., 1999; Sattentau et al., 1999; Collado et 
al., 2000). The gp120 glycoprotein has been observed to elicit both a neutralizing 
(NAb) as well as a non-neutralizing antibody response during HIV infection (Wyatt 
et aI., 1998 8) . The large majority of antibody responses raised against gp120 in 
HIV-infected people are found to be non-neutralizing (Burton, 1997; Burton et aI., 
2000). Non-neutralizing antibodies are often directed against regions of gp120 that 
may be hidden in the assembled trimer (Wyatt et al., 1998 B). For this reason it is 
believed that the humoral immune response during HIV infection is directed 











al., 1997(A) and (B)). This deduction made by Burton (1997), is consistent with the 
kinetics of envelope processing and rapid turnover of infected cells. It is observed 
that only a small fraction of gp160 is processed into mature gp120 in infected cells 
(Willey et al., 1988). Burton (1997) has suggested that during rapid turnover of 
infected cells, large amounts of gp160 are released. This should primarily target a 
strong initial immune response to gp160, which may suppress the immune 
response towards lower concentrations of the mature envelope (Trkola et al., 1996 
A). Alternatively, NAbs access the functional envelope glycoprotein complex and 
bind epitopes near the receptor or co-receptor binding sites (Wyatt et al., 1998 B). 
NAb responses in vivo can take months or years to develop (Morris, 2002), which 
would allow HIV infection to be firmly established in the host (Burton, 1997). The 
importance of priming B-cell memory NAb immune responses is clearly highlighted 
in a study conducted by Buckner et al., (2004), who utilised HIV-envelope 
glycoproteins as immunogens to stimulate NAb responses in macaques. As 
expected, vaccinated macaques failed to develop a completely sterilizing immunity 
but were able to control plasma viraemia levels as a result of rapidly induced NAbs 
and remained disease free for the entire 3-year observation period. The 
unvaccinated control group also developed a NAb response to the challenge 
chimaeric simian human immunodeficiency virus (SHIV). although at a much 
slower rate. Animals in this group rapidly progressed to a diseased state and 
fatalities were observed within the observation period. 
The need for a more rapid, B-cell primed memory response is inferred in a case 











a few months following infection but this appears to exert a selective pressure that 
allows escape of neutralization-resistant mutants (Richman et al., 2003). This then 
necessitates a repeat of the process of having to stimulate new NAbs, which are 
able to recognise the new predominant circulating neutralization-resistant mutants. 
Priming NAb B-cell memory thus does appear to have played a crucial role in 
controlling viral replication in the infected host. 
The oligomeric form of gp120 is known to display a limited array of epitopes 
recognisable by neutralizing antibodies. The accessibility of these epitopes is 
better understood when observing the core structure of gp120 (Figure 1.2A). The 
gp120 core consists of 2 domains: an inner domain that faces the trimer axis and 
gp41, and the outer domain that is exposed on the surface of the trimer (Wyatt et 
aI., 1998 B). There is also a third region referred to as the bridging sheet, which 
does not belong to either domain completely. In this core structure variability is 
also associated with the surface of the outer domain core proximinal to the V4 and 
V5 loops. Variability here is contributed by the A, B, C, D and E surface loops, 
which serve as potential N-linked glycosylation sites in the gp120 core in this half 
of the protein (Wyatt et al., 1998 B). As most carbohydrate moieties are recognised 
as self to the immune system, this renders this region of gp120 less visible to 
immune surveillance and thus it is referred to as the silent face of the protein 
(Wyatt et al., 1998 A, B). In addition to this, a neutralizing as well as a non-
neutralizing face of gp120 has been identified (Figure. 1.2A). The neutralizing face 
is situated at the base of the trimeric complex and contains the co-receptor binding 























Figure. 1.2. This illustrates the core structure of the gp120 envelope protein. (A) Shows approximate 
locations of the faces of the gp120 core, defined by the interaction of gp120 and antibodies. The 
molecular surface accessible to neutralizing ligands is shown in white. The neutralizing face of the 
complete gp120 glycoprotein includes the V2 and V3 loops, which are found adjacent to the surface 
shown. The approximate location of the gp120 face that is poorly accessible on the assembled envelope 
glycoprotein trimer and therefore elicits only non-neutralizing antibodies is shown in magenta. The 
approximate location of an immunologically 'silent' face of gp120, which roughly corresponds to the 
highly glycosylated outer domain surface, is in blue. (8) This shows the ribbon diagram of the gp120 core 
seen from the perspective of CD4, and is oriented with the viral membrane at the top of the figure and the 
target cell membrane at the bottom. The inner gp120 domain is shown in red and the outer domain in 
yellow; the 'bridging sheet' is blue. The Nand C tennini of the truncated gp120 core are labelled, as are 
the positions of structures related to the gp120 variable regions V1-VS. The gp120 surface is implicated 
in binding to the CCRS chemokine receptor. Images and penn iss ion for use kindly provided by Dr 
Richard Wyatt, Chief, Structural Virology Section, Vaccine Research CenterlNlH, (Wyatt et al., 19988). 
face has been identified to contain the CD4 receptor-binding site (Wyatt et aI., 
1998 B). 
Only a few target sites on gp120 have been recognised to act as NAb epitopes and 
these include the epitopes defined by the MAbs 2G12 and IgG1b12 (Burton, 1997). 
Epitope 2G12 binds to a region defined as a cluster of high-man nose type 
oligosaccharides proximal to the surface implicated with co-receptor binding near 
the base of the V3 loop on HIV-1 gp120 (Morris, 2002; Calarese et aI., 2003; Wang 











region proximal to the CD4-receptor binding site. is located in the membrane 
proximinal part of the gp41 glycoprotein (Muster et al., 1994). Gp41 has also been 
shown to contain broadly neutralizing ligands recognized by the 2F5 and 4E10 
antibodies (Zwick et al., 2001; McGaughey et al., 2004; Cardoso et al., 2005). 
1.2.2 V3 Loop 
The third variable loop (V3) in gp120, located between amino acids Cys301 -
Cys336, is critical for defining co-receptor tropism of the virus (Fields et al., 1996). 
V3 induces one of the most potent NAb responses able to bind both HIV virions 
and infected cells, and has thus been termed the principal neutralizing domain 
(PND) of the virus (D'Souza et al., 1991; Javaherian et al., 1991; Spear et al., 
1992, Rizzuto et al., 1998, 2000). The potency of the immune response against V3 
can be attributed to the important role it plays in cell tropism (detection of target 
cells), cytopathicity and fusogenicity (Hoffman et aI., 1999; Hung et al., 1999; 
Hwang et a/., 1991; Wang et al., 1999). As a consequence of these key functions 
attributable to V3 during the early stages of virus infection, the potential ability of 
V3-specific antibodies to neutralize virus infection is evident. Mediation of virus 
neutralization can proceed by either blocking the binding of gp120 to chemokine 
co-receptors or inhibiting virion entry at a step after virus attachment (Trkola et al., 
1996; Hill et al., 1997). Such methods of neutralization have also previously been 
demonstrated in an assay where synthetic V3 peptides were capable of blocking 
HIV infection of primary lymphocytes and macrophages (Yahi et al., 1994). 
Several studies have revealed that V3 is a major determinant of chemokine 











demonstrated that V3-deleted forms of gp120 are unable to bind CCR5 receptors 
even when CD4 receptor binding has occurred at wild-type levels (Trkola et a/., 
1996). Subsequent research by Cormier et a/. (2000, 2001 and 2002) has revealed 
that the interaction between soluble gp120-CD4 complexes and CCR5 N-terminal 
sulfopeptides requires amino acid residues which primarily reside within the V3 
stem and C4 regions of gp120. Residues within the V3 crown, on the other hand, 
have been shown to play an important role in soluble gp120-CD4 complex binding 
to cell surface CCR5, where they interact with the extracellular loop regions of 
CCR5. Thus entry into target cells is dependent on the subsequent interactions 
between gp120 and both the CD4 target receptor and the N-terminal domain of the 
CCR5 or CXCR5 co-receptors. Subsequent research has also suggested that 
specific residues within V3 may also play an equally important role in mediating the 
post-entry integration of viral DNA (Suphaphiphat et al., 2003). 
The binding of antibodies to V3 is found to interfere with gp120-CCR5 binding 
(Trkola et al., 1996). The major function of CD4 receptor binding has been 
suggested to involve induction of conformational changes in gp120 that contribute 
to the exposure of the chemokine co-receptor binding site (Sattentau et al., 1991; 
Bandres et al., 1998). However, some clinical laboratory isolates of HIV no longer 
depend on CD4 for entry, requiring only chemokine receptors instead (Clapham et 
al., 1992). Several HIV-2 strains have demonstrated an ability to infect CD4-
negative cell lines. Clapham et al., (1992) have suggested that chemokine 
receptors may represent the" primordial 0 bligate receptors" and the use of C 04 
receptors may have evolved to enhance chemokine receptor binding. Targeting an 











response directed towards CD4. A study by Reeves et al (1997), in which 
molecular clones with a C D4-independent tropism were used, demonstrated the 
critical residues required for CD4-independent tropism to reside within V3. 
Modelling studies on gp120 have suggested that the V2 and V3 loops, which 
reside opposite one another in the structure, may play a role in shielding the 
conserved elements of the chemokine receptor (Wyatt et al., 1998 B). An immune 
response directed towards the chemokine receptor will therefore not always be 
completely possible, although it should be possible to block chemokine interaction 
by targeting an immune response towards V3. 
1.2.3 V3 loop sequence conservation 
In spite of V3 being a variable domain, relatively conserved domains within it have 
nevertheless been identified. These conserved domains reside within the crown of 
V3 (306-322) in HIV-1 isolates, whereas variable domains generally reside within 
the 10-15 amino acids occurring on either side of the crown (Spear et al., 1994). 
The V3 monoclonal antibody 447-520 is recognized as one of the most broadly 
neutralizing antibodies and recognizes a 14 amino acid sequence that contains the 
GPxR core sequence residing at the crown of the V3 loop (Zolla-Pazner et al., 
2004; Conley et al., 1994). Similarly the 58.2 monoclonal antibody is known to 
potently neutralize T CLA H IV -1 strains, which a Iso recognises t he V 3 sequence 
that constitutes the crown of the V3 loop (HIGPGRAF) (Cabezas et al., 2000; Dong 
et a/., 2004). Several stUdies have now demonstrated the cross clade neutralizing 
activity of both polyclonal and monoclonal antibodies to V3 loop against both 
primary and TCLA HIV isolates (Gorny et al., 2002; Krachmarov et a/., 2001; 











highlighted in a study conducted by Spear et al. (1994) who analysed the relative 
contributions of V3-specific antibodies in the sera of HIV-infected individuals. Very 
high levels (30-40%) of the sera from HIV-infected persons that were capable of 
binding infected cells were V3-specific. This study also compared the ability of the 
entire g p120 protein a nd a V 3 peptide to inhibit complement stimulated by sera 
isolated from infected persons: gp120 demonstrated a 92% capacity to inhibit 
complement compared to the central epitope of V3 which displayed an 82% 
capacity. This is very significant considering that V3 only constitutes 3% of the 
gp120 amino acid sequence. 
Immune responses elicited by V3-C4 peptide chimaeric-based vaccines have also 
been shown to neutralize primary SHIV isolates. In a follow-up study, this peptide 
provided a partial protection against a SHIV-89.6 challenge in rhesus macaques 
(Liao et al., 2000; Letvin et al., 2001). Variations of V3-based vaccine candidates 
have also included Gag virus-like particles (VLPs), which present V3 epitopes 
fused to their subunit C-termini (Luo et al., 1991; 1997). In these instances, 
assembled Gag VLPs have allowed the simultaneous presentation of several V3 
peptides per VLP and have shown to stimulate NAb responses to serum of 
inoculated rabbits. The inoculation of the Gag VLPs alone (no V3 epitope 
presented) did not stimulate a similar NAb response. Humoral immune responses 
in these cases (stimulated by Gag VLPs) and others have been fairly type specific, 
very few demonstrating ability to recognize and neutralize heterologous isolates 
despite displaying several different V3 epitopes in tandem. Cytotoxic T lymphocyte 
(CTL) responses to these Gag-V3 VLPs were also analysed (Luo et al., 1997). 











response and lysed target cells displaying the V3 epitope contained in the VLPs 
used. Thus, despite the importance of the humoral immune response, it is evident 
that an effective vaccine should also stimulate the cellular arm of an immune 
response to be effective. The aforementioned studies specifically highlight the 
importance of choosing epitopes for a vaccine that induce an antibody response 
capable of neutralizing primary HIV/SHIV isolates and not only T-cell line adapted 
strains (TCLA) as indicated by several other studies (Gorny et al., 1997, 1998; 
Spenlehauer et aI., 1998). These studies indicate more promisingly that NAb 
responses can be stimulated from individual V3 peptides. This suggests that the 
"correct" 3-dimensional or native context of the peptide in gp120 is not necessarily 
imperative for stimulating NAb responses. 
The recent analysis of serum samples derived from a cohort of HIV-1 subtype-C 
infected South African sex workers was analysed (Bures et al., 2002). Extensive 
cross neutralization between the serum samples and heterologous isolates has 
suggested the presence of shared neutralization determinants. Shared 
neutralization determinants in effect is desirable for the development of a vaccine 
as it suggests that a neutralizing antibody response will have a smaller antigenic 
diversity to overcome at a regional level. During the course of this study, serum 
derived from 2 isolates, Du151 and Du179 after less than 2 years of infection were 
capable of neutralizing a large number of both HIV-1 subtypes C and TCLA B 
subtypes to a level similar to that displayed by the serum of HIV-infected non-
progressors. Sera from the subjects were also found to react strongly with the 
autologous V3 peptide and also showed a broad cross-reactivity with heterologous 











particularly strong for subjects Du151 and Du179. V3 epitopes from HIV isolated 
from these 2 individuals were selected for my study purposes. 
1.3 VACCINE DESIGNS 
Currently, several different vaccine types including DNA, protein subunit and live 
attenuated vaccines have been designed and tested against HIV in ongoing trials 
(Boyer et al., 2000; Qui et al., 1999; Morris et al., 2000; Morris et al., 2002; Bruce 
et al., 1999). Protein subunit vaccines are deemed to be one of the safer 
alternatives as HIV-specific vaccines, with the ability to potentially stimulate an 
efficient immune response without posing the threat of reverting to a virulent form 
and causing disease as demonstrated by some live attenuated vaccine models 
(Barouch et al., 2002; Arntzen, 1997). 
Traditionally, protein subunit vaccines have been produced in mammalian cell 
cultures, bacteria and yeast. These processes call for the development of highly 
specialised facilities and equipment for production, purification and storage of the 
protein products. Additional complications may arise as the prokaryotic protein 
synthesis machinery does not require post-transcriptional or post-translational 
modification mechanisms such as glycosylation, and this may lead to such 
complications as incorrect protein folding (Marino, 1991). These complications and 
the expense have made this form of vaccine production an expensive process 
(Awram et al., 2002) (Table 1.). This would severely limit access to treatments 
prepared by these methods by the most needy. The need for more cost-effective 
vaccines is highlighted annually by the approximately 2 million unnecessary deaths 











result of 20% of infants worldwide not being vaccinated against diphtheria, 
pertussis, polio, measles, tetanus and tuberculosis due to the sheer expense. 
Table1. Comparison of production systems for recombinant human pharmaceutical proteins (Ma et 
a/., 2003) 
System Overall Production Scale-up Product Glycosylation Contamination Storage cost 
cost timescale capacity quality risk 
Bacteria Low Short High Low None Endotoxins Moderate 
Yeast Medium Medium High Medium Incorrect Low risk Moderate 
Mammalian High Long Very low Very High Correct Viruses, prions and Expensive 
cell culture oncogenic DNA 
Transgenic High Very long Low Very High Correct Viruses, prions and Expensive 
animals oncogenic DNA 
Plant cell Medium Medium Medium High Minor Low risk • Moderate 
cultures differences .J 
Transgenic Very low Long Very high High Minor Low risk Inexpensive 
plants differences 
1.3.1 Vaccine Production in Plants 
Recent advances in molecular biology have provided a more cost-effective 
alternative for the bulk production of foreign proteins: this is the use of plants as 
bioreactors. This concept of using plants as a means of producing proteins for 
subunit vaccines was first introduced in 1992 by Charles Arntzen and co-workers 
(Arntzen et al., 1997; Walmsley et a/., 2003), which has since given rise to the 
concept of molecular farming. The prospect of producing foreign proteins in plants 
is particularly attractive as plants can be grown locally and do not require highly-
specific growth nutrients or conditions and facilities (Awram et aI., 2002). The 
production of foreign proteins within plants grown locally for vaccine purposes 
could also resolve the logistical and economic challenges of transporting the 
vaccine over long distances. It has been estimated by Evangelista et al. (1998) that 












Ecoli. As indicated by Ma (2000), the prospect of producing vaccines within plants 
should. apart from lowering production costs of newly-developed vaccines, also 
reduce the costs of already-existing protein subunit vaccines. Several provisionally 
successful recombinant subunit vaccines have been produced in plants (Table. 2). 
Table 2. Recombinant subunit vaccines produced in plants (Ma et a/.J 2003) 
. Foreign PEgtein expressed Plant host 
• Hepatitis B virus envelope protein Tobacco First vaccine candidate expressed in plants; 
third plant derived vaccine to reach clinical 
trials stage 
Rabies virus glycoprotein . Tomato First example of an "edible vaccine" expressed 
in edible plant tissue. 
Escherichia coli heat-labile 0, potato First plant vaccine to reach clinical trials stage 
enterotoxin 
Norwalk virus CP Potato Second plant vaccine to reach clinical trials 
staQe 
Diabetes auto antigen Tobacco, potato First plant-derived vaccine for an autoimmune 
disease 
Cholera B subunit Tobacco, potato First vaccine candidate expressed in 
chloroplasts 
~Chole," toxin Band A2 subunits, Potato First plant derived multivalent recombinant 
rotavirus enterotoxin and antigen designed for protection against several 
enterotoxigenic E. coli fimbrial diseases 
I antiQen fusions 
Porcine transmissible Tobacco, maize First example of oral feeding inducing 
gastroenteritis virus glycoprotein protection in an animal 
S 
Foreign protein expression systems in plants can be established in 2 main ways. 
The first involves the generation of transgenic plants, which involves the 
permanent insertion of the foreign gene of interest into the plant nuclear or 
chloroplast genome (Riga no et al., 2005). Several antigens including the Hepatitis 
Band E virus surface antigen, rabies virus glycoproteins, Human papillomavirus 
(HPV) type 16 L 1 major CP, rotavirus VP7 neutralizing protein, Escherichia coli 
heat-labile toxin, Foot and Mouth disease virus VP1 protein and many others have 











plants (Mason et al., 1992; Ma et al., 2003; Mc Garvey et al., 1995; Varsani et al., 
2003; Wu et al., 2003; Kang et al., 2004; Sun et al., 2003; Daniell et al., 2005). 
The major alternative is the use of recombinant virus-derived plant expression 
vectors, which allow the hopefully high-level transient expression of a foreign gene 
of interest. Both these different techniques have their own advantages and 
disadvantages. A comprehensive knowledge of plant tissue culture is required 
when generating transgenic plants. This process is drawn out and labour-intensive, 
and generally transgenic plants are unable to reach the high expression levels 
attainable by viral expression vectors. Recombinant viral vectors on the other 
hand, have the potential to rapidly produce high levels of the protein in the infected 
plant within 1-4 weeks of inoculation (Awram et al., 2002). These high expression 
levels are facilitated by the ability of the virus to spread systemically throughout the 
infected plant and produce the foreign protein in all infected cells. Optimal protein 
expression levels can be determined by the protein, the viral vector used, and the 
type of plant to be infected. 
1.4 PLANT VIRAL VECTORS 
Potential plant viral vector candidates used in previous research include the 
isometric viruses Cowpea mosaic virus (CPMV), Tomato bushy stunt virus (TBSV) 
and Caulimovirus based vectors (Awram et al., 2002; Usha et aI., 1993; Joelson et 
al., 1997; De Zoeten et al., 1989). Helically-assembling plant viruses can also be 
added to this repertoire of plant viral vectors, and these include the tobamovirus-
based vectors, Alfalfa mosaic virus-derived (AMV) vectors, Potexvirus-based 











1997; Sugiyama et al., 1995, Marusic et al., 2001). Tobacco mosaic virus (TMV), a 
member of the Tobamoviridae, is one of the more prominent vectors. Historically 
TMV has been one of the most well studied viruses. 




Untitled 30 kOa 17 kOa 
Movement protein Coat protein 
Figure. 1.3. Illustrating all open reading frames within a linearized representation of the TMV 
genome (http://www.biosource-technologies.comlgenead.html) 
1.4.1 TMV Plant Viral Vectors 
Several investigators have exploited the potential of the TMV CP (CP) in vaccine 
development to generate CP hybrids that display a variety of foreign epitopes 
including those from malaria (PlasmOdium), HIV gp120, Influenza virus and Murine 
hepatitis virus (Turpen et al., 1995; Sugiyama et al., 1995; Koo et a/., 1999). 
Numerous other investigators have also succeeded in stimulating the production of 
significant levels of peptide-specific antibodies using these TMV CP hybrids 












TMV is a plus-sense single-stranded RNA (ssRNA) virus whose genome consists 
of 6395 nucleotides, and contains only 4 open reading frames (ORF) (Figure. 1.3) 
(Goelet et aI., 1982). TMV expresses 3 genes; a 126kDa as well as a 183kDa 
protein are expressed from the 5' end of genomic RNA by means of a leaky 
translational stop codon directly (Yusibov et al., 1999). These 2 proteins are known 
to form a replicase complex required for efficient replication (Ishikawa et al., 1991). 
Other proteins translated from subgenomic RNAs during viral replication include a 
30kDa movement protein, which is required to facilitate passage of the virus 
particles from cell to cell via the plasmodesmata (Wolf et al., 1989) and a 17.5kDa 
CP, which is required for the long distance movement of the virus within and 
between plants. 
The N- and C- termini of the CP are known to protrude on the exterior surface of 
the TMV virion, which make them ideal for epitope presentation (Figure. 1.4C) 
(Namba et aI., 1989). Epitopes fused to the purified CP can be presented in an 
aggregated or particulate form as the CP monomers at low pH are capable of self-
assembly by aggregating into rod-like particles independent of viral RNA, of which 


















Figure. 1.4(A) and (8) display 3-dimensional data of the assembled rod-shaped TMV vlOon 
(www.ppws.vt.edu/-sforza/tmv/tmv.html) All content and images ®Copyright Peter Sforza, 2001; (C) 
Shows a ribbon diagram of a TMV coat protein monomer; the N- and C-termini lie next to one another 
and are exposed at the surface of the assembled rod (http://www.biologie.uni-hamburg.delb-
online/e35/7.htm) @ Peter v. Sengbusch. Images were kindly provided by the indicated researchers. 
The TMV CP has been shown to be strongly immunogenic in the aggregated state 
or as virions, and probably contains T-cell epitopes (Dr K. E. Palmer, LSBC, 
personal communication). This property is quite noteworthy, as recombinant 
"display" particles can almost certainly strongly enhance the immunogenicity of a 
fused epitope. Enhanced V3 peptide immune responses have been demonstrated 
by means of using a highly immunogenic Hepatitis B surface antigen (HBsAg) to 











elicited humoral immune responses against both viruses within 3-6 weeks, which 
peaked at 6-12 weeks and remained stable for 25 weeks. This observed response 
was far superior in comparison to the use of gp160 peptide alone, which only 
induced a slow and low-titred anti-V3 response at 12 weeks post-inoculation. This 
demonstrated the ability of an immunogenic carrier protein to act as an adjuvant 
enhancing the weak anti-V3 response (Fomsgaard et aI. , 1998). 
Properties that promote the use of the TMV as a vector for gene expression within 
plants include the fact that the 17.5 kDa TMV CP is capable of being expressed at 
high levels in the infected plant. The viral CP has already been shown to 
accumulate to levels as high as 10% of the infected dry leaf mass (Fraser et al., 
1987; Yusibov et aI., 1999). This ability to rapidly produce high levels of protein has 
been credited to the fact that TMV is an RNA virus. TMV has also displayed a rapid 
systemic spread within a range of host plants (Donson et al., 1991). Replication is 
limited to the cytoplasm and not the nucleus and thus the absence of nuclear 
integration coupled to viral replication kinetics enables rapid production of proteins 
(http://www.biosourcetechnologies.com/genead.html). A property of immense 
significance is that the TMV RNA genome can be used to make cDNA clones that 
are easily modified to allow foreign gene expression (Shivprasad et aI., 1999; 
Donson et al., 1991). Another important fact about TMV is that it has a very broad 
host range, and one of its primary host species - Nicotiana tabacum or tobacco, is 
also one of the highest biomass and soluble protein-producing crops in the world 
(Yusibov et aI., 1999). As TMV is a plant virus it does not pose the threat of 












As TMV is an RNA virus, this could deter some who consider using it as a potential 
vector because of the low fidelity of RNA polymerases (replicase) (Yusibov et aI., 
1999). A study conducted by Kearney et al. (1993) examined the accumulation of 
errors within a TMV-derived vector over a period of 6 months and 10 passages 
from plant to plant. Of the viral RNA isolated and sequenced, no mutations were 
identified. Similar results obtained with another RNA virus based vector, TBSV, 
corroborate the finding that these vectors are potentially quite stable, as the vector 
retained the correct epitope sequence through a series of 6 sequential passages 
(Joelson et al., 1997). Despite the stability, however, all recombinant viruses used 
in this study were found to lose their insert eventually. This may work in favour of 
use of the vector, as "escapes" can almost be guaranteed to revert to "wild-type" 
on serial transmission preventing expression of foreign gene in other nearby crops. 
It has been established that peptides are efficiently presented to the immune 
system in repetitive arrays (Broekhuijsen et al., 1986; Lo-Man et a/., 1993; 
Lowenadler et al., 1990; Zheng et al., 1993). Such displays allow for more efficient 
cross-linking of antigen-specific immunoglobulins on B-cells, which leads to B-cell 
proliferation and antibody production. A study conducted by Oscherwitz et a/. 
(1999) has compared the ability of immunogens containing single as well as 8 
tandemly repeated copies of V3 to elicit an immune response. The study revealed 
that the tandemly repeated immunogen was capable of inducing an approximately 
3D-fold greater antibody response compared tot hose elicited by t he monomeric 
immunogen. Similarly Yusibov et a/. (1997) used a recombinant TMV expression 
system, which utilised the AMV CP to express V3 peptide from HIV. The 











humoral immune response, which resulted in up to 80% neutralization of the HIV-
1/MN isolate. 
1.5 PROJECT OUTLINE AND OBJECTIVES 
The aim of this study was to develop a peptide-based vaccine capable of inducing 
a NAb response to HIV-1 subtype C, the predominant subtype circulating in sub-
Saharan Africa. The V3 PND was identified as the epitope of choice to stimulate 
the NAb response. A TMV-based expression system was selected as a means of 
efficiently expressing, producing and presenting the V3 loop epitope. The foreign 
V3 loop epitopes were fused to different positions in the TMV CP, to potentially 
allow the display of these epitopes on the surface of the assembled TMV virion: 
theoretically, this could allow display of approximately 2000 copies of the V3 
peptide on the outer TMV virion surface. Both TMV vector systems (CP fusions) 
and V3 peptides have shown promise in their individual respects as an efficient 
expression system and a potent Nab-stimulating immunogen in the varying 
contexts discussed earlier. The combination of these 2 factors could therefore 
present a potent HIV NAb stimulating vaccine candidate that if successful, could 
form part of a combination therapy regimen. As the proposed TMV based vaccine 
candidate's production is plant based, this study aimed to enable a cost-effective 
means of vaccine production, which is one of the primary aims for vaccine 
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A primary concern when investigating a potential vaccine is whether the selected 
epitope/s presented to the immune system are capable of stimulating an adequate 
immune response (capable of clearing an infection), be it humoral or cellular. The 
aim of this study was to stimulate the humoral arm of the immune response and 
determine whether a significant HIV NAb response could be stimulated with a 
recombinant carrier particle. In particular, an epitope capable of stimulating a 
broadly cross-NAb response to the predominant HIV-1 subtype circulating in sub-
Saharan Africa was most desirable. As discussed earlier (chapter 1 page 11), the 
HIV-1 subtype C gp120 V3 (PND) epitope was identified as the epitope of choice 
to elicit this immune response. 
NAb responses were recently analysed in a cohort of South African sex workers 
infected with HIV-1 subtype C (Bures et a/., 2002). Sera from the subjects were 
found to react strongly with the autologous V3 peptide and also showed a broad 
cross reactivity with heterologous subtype C V3 peptides. V3-specific reactivity and 
neutralization activity of sera was particularly strong for subjects Du151 and 
Du179. In some instances Du151 serum was shown to react more strongly with 
heterologous V3 sequences than their autologous sera. Prior research on Du151 
and Du179 subject-derived isolates revealed that Du151 isolates used the CCR5 
receptor while Du179 isolates were dual tropic, using both CCR5 and CXCR4 as 
co-receptors (van Harmelen et al., 2001). Dual tropism is an uncharacteristic trait 
of subtype C viruses and is in general attributed to an increase in positive charges 
from arginine residues within V3. Sequencing has shown that the increased 











position 290 (which is located near the base of the V3 loop), which increased the 
overall positive charge to +6. This is characteristic of CXCR4 co-receptor tropism 
(van Harmelen et al., 2001). Another uncharacteristic trait of V3 from DU 179 
isolates identified in this study is the 34 amino acid length as opposed to the 
normal 35 amino acid length. V3 peptides derived from the Du151 and Du179 
isolates therefore serve as contrasting candidates for stimulating NAb responses 
and both were selected for this study. For the purposes of this study, HIV isolates 
derived from subjects Du151 and Du179 will be referred to as Du151 and Du179 
respectively. 
As mentioned previously, the TMV CP can accommodate the ligation of epitopes at 
various positions that allow for the presentation of the foreign epitope on the 
surface of the assembled virion. This ability to manipulate the RNA virus genome 
arises due to the fact that the viral genome can be presented in a cDNA cloning 
vector form, which later is in-vitro transcribed to facilitate viral infection. Three 
TMV-based cloning vectors were used in this study. They allowed for the fusion of 
V3 epitopes to the N-terminus, C-terminus or in the 60S loop regions of the TMV 
CPo Traditionally, TMV CP fusions have not exceeded approximately 20 amino 
acids in length, suggesting that larger epitopes would sterically hinder TMV virion 
assembly and may affect virion solubility (Sugiyama et al., 1995; Yusibov et aI., 
1997; Koo et aI., 1999; Staczek et al., 2000; Wu et al., 2003). To prevent this 











This chapter describes the assembly and construction of recombinant V3-
presenting TMV vectors from the base TMV vectors provided by Large Scale 











2.2 MATERIALS AND METHODS 
2.2.1 Assembly of V3 epitopes 
HIV-1 subtype C V3 PND amino acid sequences derived from patients Du151 and 
Du179 were kindly provided by Dr Lynn Morris (National Institute for 
Communicable Diseases, Johannesburg, South Africa). 
Du151: N- NNNTRKSIRIGPGQTFYATGEII-C (23 amino acids) 
Du179: N- GNNTRKSIRIGPGQAFYTNHII -C (22 amino acids) 
These epitopes were cloned into the appropriate LSBC TMV-based cloning vectors 
(pLSB2295, pLSB2109, pLSB2296; Dr K.E. Palmer, LSBC, CA, USA) at the Ncol 
(Ncol = 5'-CCA TGG-3') and NgoMIV (NgoMIV = 5'-GCC GGC-3') restriction 
enzyme cloning sites, resulting in fusion of the epitope at either the N-terminus 
(pLSB2295) or C-terminus (pLSB2109) or to the 60S loop (pLSB2296) (Appendix 
B 2,4, 6). 
The epitope-encoding sequences were therefore modified as follows, each 
epitope-encoding sequence averaging approximately 70 base pairs (bp) in length. 
The oligonucleotides synthesized by the Oligonucleotide Synthesizing Service of 
the Department of Molecular and Cell Biology, University of Cape Town could not 
exceed 40 bp in length if they were to retain any relative degree of accuracy. To 
facilitate the synthesis of the V3 epitope encoding sequence I therefore decided to 











In addition, Du151 and Du179 sequences needed to be synthesized to have an 
Ncol site at the 5'-encoding end and an NgoMIV site at the 3'-encoding end to 
allow for easier cloning. 
As mentioned previously, the V3 PND-encoding sequence was truncated to avoid 
steric hindrance of virion assembly. Appropriate truncation of each epitope was 
accomplished by removing the first and last 4 amino acids from both Du151 and 
Du179 encoding sequences resulting in 2 overlapping epitope-encoding regions 
highlighted in Figure 2.1. 
Du151: (a) 
6'-CC ATG GGT AAC AAC AAC ACC CGG AAG AGC ATC CGG ATC GGC CCC GGC CAG ACC TTC TAC GCC ACC GCC GGC-3' 
N N N T R K S R G P G Q T F VA T 
Du151: (b) 
S'-CC ATG GOT CGG AAG AGC ATC CGG ATC GGC CCC GGC CAG ACC TIC TAC GCC ACC GGC GAG ATC ATC GCC GGC-3' 
R K S R G P G QT F V AT G E 
Du179: (a) 
6'-CC ATG GGT •••••• CGG AAG AGC ATC CGG ATC GGC CCC GGC CAG GCC TTC TAC ACC GCC GGC-3' 
R K S R G P G Q A F VT 
Du179: (b) 
6'-CC ATG GGT eGG AAG AGe ATC eGG ATC GGC CCC GGC CAG Gec TIe TAC ACC •••••• GCC GGC-3' 
R K S R G P G Q A F YT 
Figure 2.1 This shows the 4 different V3 loop epitope encoding sequences that were synthesized 
for cloning into the pLSB vectors. The highlighted areas indicate the regions where the Du151, 
Du179 (a) and (b) epitopes differ as a result of the epitope truncations. From the highlighted areas 












2.2.1.1 peR Assembly Strategy 
The High Fidelity peR System (Roche) was used as per vendor-directed 
protocol (www.roche-applied-science.com/pack-insertl1732641 a. pdf). The 
peR assembly strategy involved dividing the epitope-encoding sequence into 
4 overlapping oligonucleotides for each epitope (Appendix e(I)). 
Oligonucleotides (A) and (e) encompassed the forward strand, while (8) and 
(0) encompassed the reverse strand. These oligonucleotides then via a 2 
stage peR indicated below (Figure 2.2) were annealed ((A to 8) and (e to 0)) 
and then amplified in a 2 stage peR (Figure 2.2). The indicated intermediate 
peR products are shown in figure 2.2. The intermediate oligonucleotides 
generated, i.e. the elongated oligonucleotides A and 0, annealed at their 
complementary regions and completed the entire epitope-encoding 
sequence. Thus at the end of stage 1, a pool of nucleotides existed that 
included those encoding the correct epitope sequence as well as others that 
resulted from the annealing of oligonucleotides 8 and e, which clearly cannot 
be amplified. A second stage of peR was employed to more accurately 
define and concentrate the required epitope-encoding sequence. This second 
stage produced more specific product by using the external forward and 
reverse oligonucleotides/primers A and O. 
2.2.1.2 peR compositions: 
For the stage 1 peR a 25 pmolllli working stock dilution of each 
oligonucleotide was made and the 4 oligonucleotides (A, 8, e, 0) combined in 
equimolar amounts to form the oligonucleotide mixture. Each reaction was 











components of the High Fidelity PCR System (Roche), which included 1 x high 
fidelity buffer, 2.5mM MgCb, 0.125mM dNTP mix, 1.75 units high fidelity 
enzyme mix, 2fll (25pmollfll) oligonucleotide mixture, 36.5fll dH20 (See 
reaction temperature profile Appendix C(II)). 
The stage 2 reactions were also carried out in a final volume of 50fll. 
Reactions were carried out using components of the High Fidelity PCR 
System (Roche), which included 1 x high fidelity buffer, 2mM MgCI2 , 0.125mM 
dNTP mix and 1.75 units high fidelity enzyme mix. Reactions also contained 
1 ~I oligonucleotides A and 0, 36.25fll dH20, and 1.25fll stage 1 PCR product 
(which constitutes a 1/40 dilution of stage 1 product, see reaction temperature 
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Figure 2.2 Diagrammatic representation of the peR assembly process used for the 











2.2.2 General Cloning strategy used for inserting the epitope encoding DNA into 
sequencing and expression vectors 
Assembly PCR products were initially ligated into the pGEM®-T Easy 
cloning/sequencing vector (Promega) (DNA insert ligations to either pGEM®-T 
Easy or pLSB vectors were routinely carried out in 1 O~I volumes using 1 unit of T 4-
DNA ligase (Roche). PCR product ligation into the pGEM®-T Easy vector was 
performed using reagents provided in the pGEM®-T Easy kit following 
manufacturers protocol in 30:1, insert: vector ratios.) and recombinant plasm ids 
(pGEM+151a, 151b, 179a, 179b) were used to transform DH5a E. coli competent 
cells as described in Appendix A(VI). Plasmid DNA was isolated (Appendix A(II» 
and the insert sequenced using an M13 forward primer (Appendix A(VII» provided 
with the pGEM®-T Easy kit to verify the amplified sequence. DH5a E. coli 
transformants that were identified to contain the correct V3 epitope-encoding 
sequence were used for a large-scale plasmid DNA isolation (Appendix A(II». 
Recombinant plasmid DNAs were digested in Ncol (Promega) restriction enzyme, 
Digests were carried out using 1 unit of enzyme/~g of DNA and incubated at 37°C 
for 2 hours before analysis. Supplier provided buffers and bovine serum albumin, 
which accompanied the specific enzyme, was used in each digest as per suppliers 
protocol. Digests were followed by column purification of digested DNA (Appendix 
A(V». Column purified DNA was then digested in NgoMIV (New England Biolabs) 
restriction enzyme. The V3-encoding sequences were gel purified as described in 
Appendix A(V). 
The V3-encoding fragments were ligated into the Ncol and NgoMIV restriction 











ligations to the pLSB vectors were carried out in 10:1 (insert:vector) ratios. 
Recombinant DNAs were used to transform competent E. coli DH5a cells 
(Appendix A(VI» and plasmids were purified using a large-scale DNA isolation 
protocol (Appendix A(II». The sequences of recombinant clones were verified by 
sequencing the pLSB2109 and pLSB2296 recombinants with the TMV CP forward 
primer (Appendix A(VII», while the pLSB2295 recombinants were sequenced with 











2.3 RESULTS AND DISCUSSION 
2.3.1 Assembly ofV3 epitopes (peR assembly) 
The V3 epitopes were successfully assembled using an assembly peR technique. 
The expected approximately 75 bp band was identified in each assembly reaction 







1 2 3 4 5 6 
+/-75 bp band 
Figure 2.3 PCR assembly products resolved on a 2% agarose gel. Lane 1 contains a APst 
DNA size marker, lanes 2 and 3 show the 0 DNA controls for stage 1 and 2 respectively 
and Lane 4 contains the Stage 1 experimental assembly PCR product, Lanes 5 and 6 
show identical samples loaded in duplicate from the stage 2 V3 loop epitope assembly. 
It is evident from duplicate lanes 5 and 6 (stage 2 peR products) compared with 
lane (4) (stage 1 peR product), that the stage 2 final product is a more defined 











2.3.2 Cloning of Assembled V3 Epitope into Expression Vectors 
The PCR product was screened to identify correctly assembled V3-encoding 
sequences by cloning the stage 2 PCR products into the pGEM T®-Easy 
cloning/sequencing vector (Appendix 81), and sequenced using the M13 forward 
primer. The Neol and NgoMIV restriction enzyme digests of selected clones 
excised the insert from the pGem®-T Easy vector, which resulted in the expected 
approximately 75 bp band as well as an approximately 370 bp band as a result of 
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(+/-75 bpI 
Figure 2.4 DNA products from an Ncol/NgoMIV double digest on a 1% agarose gel. 
Lane 1 contains the APst DNA size marker, lane 2 contains the undigested pGem®-T 
Easy vector, lane 3 contains the stage 2 assembly peR product as a size marker, lane 
4 contains the Ncol/NgoMIV double-digested recombinant pGem®-T Easy vector from 











As seen in Figure 2.4, the V3-epitope encoding bands were then cut out from the 
gel and purified from the gel slice. 
V3 loop-encoding sequences were ligated to the Ncol- and NgoMIV- digested 
pLSB2295, 2109 and 2296 vectors (Appendix B2, 4, 6). The recombinant pLSB 
vectors were screened by sequencing using pLSB CP forward and reverse 
sequencing primers (Appendix A(VII)). Sequencing of recombinant clones showed 
that each of the pLSB2295, 2109, 2296 vectors contained each of the Du151 a, 
151 b, 179a and 179b epitope-encoding sequences in the correct reading frame as 
indicated by the sequence translations that follow: (Figure 2.5 A-L) 
(A) 
pLSB2295 + Du151 (a) (N-terminal fusion) translation 
Total amino acid number: 181, MW=19889 




21 A G S Y SIT T P S Q F V F L S SAW 
121 GCCGACCCAATAGAGTTAATTAATTTAT GTACTAAT GCCTTAGGAAATCAGTTTCAAACA 
41 A D PIE LIN L C T N A L G N Q F Q T 
181 CAACAAGCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAA 
61 Q Q ART V V Q R Q F S E V W K P S P Q 
(8) 
pLSB2295 + Du151(b) (N-terminal fusion) translation 
Total amino acid number: 181, MW=19858 




21 A G S Y SIT T P S Q F V F L S SAW 
121 GCCGACCCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAAACA 
41 A D PIE LIN L C T N A L G N Q F Q T 
181 CAACAAGCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAA 












2295 + Du179(a) (N-terminal fusion) translation 
Total amino acid number: 180, MW=19731 




21 A G S Y SIT T P S Q F V F L S SAW A 
121 GACCCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAAACACAA 
41 D PIE LIN L C T N A L G N Q F Q T Q 
181 CAAGCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTA 
61 Q ART V V Q R Q F S E V W K P S P Q V 
(D) 
pLSB2295 + Du179(b) (N-terminal fusion) translation 
Total amino acid number: 180, MW=19822 
Max ORF: 1-540, 180 AA, MW=19822 
1 CGGAAGAGTATTCGAATTGGACCAGGACAGGCATTCTATACAAACCACATCATC 
1 M G 
61 CTTACAGTATCACTACTCCATCTCAGTTCGTGTTCTTGTCATCAGCGTGGGCC 
21 A G S Y SIT T P S Q F V F L S SAW A 
121 GACCCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAAACACAA 
41 D PIE LIN L C T N A L G N Q F Q T Q 
181 CAAGCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTA 
61 Q ART V V Q R Q F S E V W K P S P Q V 
(E) 
pLSB 2109 + Du151(a) (C-terminal fusion) translation 
Total amino acid number: 182, MW=20034 
Max ORF: 1-546, 182 AA, MW=20034 
241 GTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTTGAAAATCAG 
81 V TAL L G A F D T R N R I I EVE N Q 
301 GCGAACCCCACGACTGCCGAGACGTTAGATGCTACTCGTAGAGTAGACGACGCAACGGTG 
101 A N P T T A E T L D A T R R V D D A T V 
361 GCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGATCAGAGGAACCGGATCTTAT 
121 A IRS A INN L I VEL I R G T G S Y 
421 AATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCTCT 
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pLSB 2109 + Du151 (b) (C-terminal fusion) translation 
Total amino acid number: 182, MW=20003 
Max ORF: 1-546, 182 AA, MW=20003 
241 GTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTTGAAAATCAG 
81 V TAL L G A F D T R N R I I EVE N Q 
301 GCGAACCCCACGACT GCCGAGACGTTAGAT GCTACTCGTAGAGTAGACGACGCAACGGT G 
101 A N P T T A E T L D A T R R V D D A T V 
361 GCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGATCAGAGGAACCGGATCTTAT 
121 A IRS A INN L I VEL I R G T G S Y 
421 AATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCTC 




181 A T * 
(G) 
pLSB2109 + Du179(a) (C-terminal fusion) translation 
Total amino acid number: 181, MW=19876 
Max ORF: 1-543, 181 AA, MW=19876 
241 GTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTTGAAAATCAG 
81 V TAL L G A F D T R N R I I EVE N Q 
301 GCGAACCCCACGACTGCCGAGACGTTAGATGCTACTCGTAGAGTAGACGACGCAACGGTG 
101 A N P T T A E T L D A T R R V D D A T V 
361 GCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGATCAGAGGAACCGGATCTTAT 
121 A IRS A INN L I VEL I R G T G S Y 
421 AATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCTCT TGGCAAC 









pLSB2109 + Du179(b) (C-terminal fusion) translation 
Total amino acid number: 181, MW=19967 
Max ORF: 1-543, 181 AA, MW=19967 
A G A 
241 GTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTTGAAAATCAG 
81 V TAL L G A F D T R N R I I EVE N Q 
301 GCGAACCCCACGACTGCCGAGACGTTAGATGCTACTCGTAGAGTAGACGACGCAACGGTG 
101 A N P T T A E T L D A T R R V D D A T V 
361 GCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGATCAGAGGAACCGGATCTTAT 
121 A IRS A INN L I VEL I R G T G S Y 
421 AATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCT CGGAAG 
141 N R S S F E S SSG L V W T SAM G 
481 AGTATTCGAATTGGACCAGGACAGGCATTCTATACAAACCACATCATCIIII~' 
161 A G P A 
541 ACTTGA 












pLSB2296 + Du1S1 (a) (60S-Loop fusion) translation 
Total amino acid number: 186, MW=20300 
Max ORF: 1-558, 186 AA, MW=20300 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTTCCCTGGATCTC TAACAACAACACCCGGAAGAGCATCCGGATCGGA 
61 V G 
241 TCTGGAGACTTTAAGGTATACAGGTAC 
81 S G D F K V Y R Y 
301 AATGCGGTATTAGACCCGCTAGTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGA 
101 N A V L D P L V TAL L G A F D T R N R 
(J) 
pLSB2296 + Du1S1(b) (60S-Loop fusion) translation 
Total amino acid number: 186, MW=20269 
Max ORF: 1-558, 186 AA, MW=20269 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTTCCCTGGATCT TCCGAATAGGACCAGGACAGACA 
61 
241 GGAGACTTTAAGGTATACAGGTAC 
81 P G D F K V Y R Y 
301 AATGCGGTATTAGACCCGCTAGTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGA 
101 N A V L D P L V TAL L G A F D T R N R 
(K) 
pLSB2296 + Du179a (60S-Loop fusion) translation 
Total amino acid number: 184, MW=20025 
Max ORF: 1-552, 184 AA, MW=20025 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTCCCCTGGATCT CGAATTGGA 
61 V R S P G S 
241 CCAGGACAGGCATTCTATAC CTTCTGGAGACTTTAAGGTGTACAGGTACAAT 
81 A G PSG D F K V Y R Y N 
301 GCGGTATTAGACCCGCTAGTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATA 
101 A V L D P L V TAL L G A F D T R N R I 
(l) 
pLSB2296 + Du179b (60S-Loop fusion) translation 
Total amino acid number: 185, MW=20233 
Max ORF : 1-555, 185 AA, MW=20233 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTTCCCTGGATCTC TCGGAAGAGTATTCGAATTGGACCAGGACAGGCA 
61 V R F P G S P M G 
241 CTTCTGGAGACTTTAAGGTATACAGGTACAAT 
81 PSG D F K V Y R Y N 
301 GCGGTATTAGACCCGCTAGT CACAGCACTGTTAGGT GCATTCGACACTAGAAATAGAA TA 
101 A V L D P L V TAL L G A F D T R N R I 
Figure 2.6 A, B, C, 0, E, F, G, H, I, J, K, L shows the relevant sequence translation data for 
the pLSB2295, pLSB2109 and pLSB2296 recombinant vectors containing the 151a, 151b, 











Theoretical size estimations for TMV CPs resulting from the recombinant TMV-
based vectors averaged about of 2 kDa larger than the wild-type CP as observed 
from the CP translations above. This suggested that the recombinant and wild-type 
TMV CPs could be distinguished by means of size variation. 
As it was intended that 0 nly a segment ( 18/19 0 f 35/36 amino acids) 0 f the V3 
peptide be displayed on the TMV CP, it would probably not retain the native 
conformation and thus would be presented mostly as a linear epitope. Research 
has indicated that the binding of anti-V3 antibodies is most effective when the V3 
domain retains its conformation (Schreiber et al., 1997; Krachmarov et al., 2001). 
As demonstrated in comparative studies, serum antibodies displayed much higher 
reactivity with a conformationally correct V3 fusion protein than with linear V3 
peptides. The importance of these conformational epitopes was further 
demonstrated in a study conducted by Gorny et al. (2002) who showed that the 
strength of binding of anti-V3 antibodies to HIV virions correlates with neutralizing 
activity. The implications of this lie in the additional finding that the relative affinities 
of monoclonal antibodies were 1 to 2 orders of magnitude greater for the V3 region 
that retains its conformation than for the same epitope represented by a linear 
peptide. For this reason it may have been advisable to have inserted cysteine 
residues at positions flanking the epitope encoding sequence to enable the 
formation of the native hairpin structure through the formation of disulphide bonds. 
Studies utilising CPMV expression vectors to present gp41 epitopes have been 











CPMV gp41 chimeric particle studies have also stressed the significance of 
presenting epitopes in their native conformations in order to stimulate specific 
neutralizing a ntibody responses (Burrati et a/., 1998). A similar study conducted 
using chimeric CPMV particles has also shown that the site of insertion of a foreign 
Human Rhinovirus 14 (HRV-14) epitope in the coat protein can determine the 
overall 3-dimensional structural presentation of the foreign epitope (Taylor et a/., 
2000). The structure assumed by the HRV epitope appeared to have altered its 
immunogenic properties as polyclonal antisera raised by the epitope assuming a 
closed loop conformation had a significantly enhanced ability to bind to intact HRV-
14 particles compared with antisera raised against chimaeras presenting the same 
sequence as peptides with free C-termini. The antigen used to stimulate an 
immune response should preferably be capable of recognizing a broad range of 
different HIV-1 isolates. Gorny et al. (2002) have also shown that NAbs against 
conformational epitopes could neutralize a broad range of H IV -1 isolates, and it 
has been speculated that linear epitopes will be more type-specific in neutralizing 
activity. 
Despite this, Joelson et al. (1997) have shown that a 13-amino acid sequence of 
V3 attached to the surface of a TBSV CP was detectable with the sera isolated 
from infected individuals, and also stimulated an immune response to the foreign 
HIV epitope when the chimaeric virus was injected into mice. Marusic et al. (2001) 
have also demonstrated that VLP's presenting the linear epitope "ELDKWA" from 
the transmembrane protein gp41 were capable of inducing the production of HIV-1 

















pLSB2295 (N-terminal recombinant) 
3' 
2296 (C-terminal recombinant) 
3' 
pLSB2109 (60s-loop recombinant) 
Figure 2.6 shows the relative positions of V3~pitope insertion illustrated by the pink dot 
in the TMV coat protein ORF illustrated by the green bars in the pLSB vectors. 
In this part of the study the Du151 and Du179 HIV-1 subtype C V3 PND-encoding 
oligonucleotides were successfully assembled using an assembly PCR technique, 
each as 2 overlapping epitopes truncated at either the N- or C-terminus of the 
epitope. These resulted in epitope-encoding sequences Du151 a, Du179a (C-
terminal truncations), Du151b and Du179b (N-terminal truncations). These 4 
epitope-encoding sequences were successfully cloned into the C-terminal, N-
terminal and 60S loop region of the TMV CP in the plSB21 09, 2295 and 2296 
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TMV-based expression vectors have been successful in expressing foreign 
proteins in infected plants as either CP fusions or soluble protein, which have 
generally accumulated to high levels within the plant (Chapter 1). These high 
expression levels have in turn allowed for the development of economical methods 
to rapidly scale-up, extract and purify heterologously expressed proteins. The 
levels of the foreign protein or protein fusion produced vary and depend on several 
factors, which may include the protein itself, the vector expression system or the 
plant host (Culver, 2002). TMV has a broad host range and infects over 200 plant 
species including tobacco (Nicotiana fabacum), which is one of the highest 
biomass-producing crops in the world (Awram et al., 2002). Tobacco thus serves 
as a good host for foreign protein expression. However, it has several problems as 
it contains numerous toxic alkaloids and phenolic compounds, which can 
complicate successful purification of any heterologously expressed protein (Awram 
et a/., 2002). For this reason the tobacco relative N. benthamiana has been 
recommended as a superior organic bioreactor as it does not contain the high 
levels of toxic phenolics and alkaloids associated with tobacco. Additionally, N. 
benthamiana allows the systemic spread of even attenuated TMV infection, 
enabling the production of large amounts of heterologously-expressed protein. 
Infection entails the active replication of the recombinant virus and is manifested in 
distinct infection symptoms (leaf curling, mottling, chlorosis, necrosis, growth 
stunting). These are generally not too severe to kill the plant (Culver, 2002). In 
several cases disease symptoms within infected plants have been shown to be 











structure and charge of specific domains within the CP have been shown to 
modulate various infection symptoms and disease progression within infected 
plants (Banerjee et a/., 1995; Bendahmane et al., 1999; Dawson et al., 1988). In a 
specific example the disruption of certain CP domains by the addition of foreign 
epitopes has been shown to induce severe chlorosis and necrosis (Turpen et al., 
1995; Dawson et al., 1988; Bendahmane et al., 1999). Despite this the TMV CP 
has been shown to a certain degree to be redundant for the development of the 
typical mosaic symptoms in tobacco as mutant TMV not expressing CP still 
displayed mild mosaic symptoms in tobacco (Culver et al., 1989). Infection 
symptoms therefore are not necessarily an indication of recombinant CP 
production and virion assembly. 
I n the vectors used in these experiments the TMV cDNA is carried on a pUC 18 
plasmid backbone, which contains the T7 polymerase promoter sequence 
upstream of the TMV cDNA (Yanisch-Perron et al., 1985). This facilitates the 
amplification of the vector and allows generation of infectious RNA by in vitro 
transcription of the vector. As previously mentioned, one of the primary reasons 
that viral vectors are highly efficient is their ability to spread throughout the plant 
and express the foreign gene in all infected cells. A crucial step when attempting to 
establish a viral vector based protein expression system is to ascertain whether the 
viral vector in use is capable of efficiently surviving, replicating and spreading 
within the inoculated plant host. Success of viral vector infection though depends 
not only on how well the vector is adapted to survive in the plant but also on 
several factors with regard to how the inoculation was carried out. These factors 











plant growth conditions, inoculation of a suitable leaf and the actual inoculation 
procedure. 
In this chapter, the recombinant cDNA cloning vectors previously made are 
assessed for their ability to produce an infectious TMV genome, infect N. 
benthamiana plants and to establish a systemic infection. Several other questions 
are raised in this chapter, one of which is whether the TMV CP is able to retain the 
V3 insert 0 r whether it reverts to a wild-type form. Both a V3 and T MV-specific 
antibody are used to distinguish wild-type and recombinant CPs. As the primary 
aim of this study was to create a multivalent V3 display particle, virion assembly is 
important: thus, I investigated whether t he presence 0 f t he V 3 epitope s terically 












3.2 MATERIALS AND METHODS 
3.2.1 In vitro transcription 
Capped transcripts from full-length recombinant TMV cDNA clones were generated 
using the Ribomax™ Large Scale RNA Production System - T7 kit (Promega). 
Transcription reactions were carried out according to the manufacturer's 
instructions using 5)1g of template DNA per 50)11 reaction. Prior to the transcription 
reaction, DNA templates were treated with 1 u/)1g DNA of human placental RNase 
inhibitor (Roche) for 1 hour at 37° C. After synthesis RNA samples were stored at 
-70° C. Results of the in vitro transcription were determined by electrophoresis on 
a 1 % TBE agarose gel (Appendix A(V)). Two microlitres of transcribed RNA was 
loaded onto the gel and a total of 300ng of untranscribed plasmid DNA was also 
loaded as a control. 
3.2.2 Inoculation of plants and growth conditions 
Nicotiana benthamiana seeds (LSBC 2002, K.E. Palmer, LSBC, CA, USA) were 
sown individually in seedling trays and covered with plastic until they had 
germinated. Seedlings were then transplanted after 3 weeks into pots. By 5 to 6 
weeks the plants were ready for inoculation. Plants were grown at 45% humidity, a 
constant temperature of 28° C and subjected to 16 hours of light and 8 hours of 
dark. Lighting was supplied by 4 high-output fluorescent lamps (Phillips L58W/205) 
suspended 50cm above the plants. Plants were inoculated by means of 
mechanical abrasion of the leaf surface. Each inoculation used 7.5)11 of each 50)l1 
in vitro transcription reaction with an RNase free abrasive powder (Celite), which 











visibly abraded. Each TMV construct was inoculated onto a set of 6 plants which 
were monitored daily for the presence of infection symptoms. 
Systemic spread was usually visible 10 days post infection (dpi), at which point 25-
35g of leaf material was harvested from each set of plants and used for TMV 
extraction. 
3.2.3 TMV extraction protocols 
TMV was purified from infected plants 10 dpi as described elsewhere (Chapman, 
1998). 
3.2.3.1 Wild-type TMV 
Harvested leaf material (25-35g) was homogenised in liquid nitrogen and 
resuspended in 60ml 50mM phosphate buffer, pH8 containing 1 % 2-
mercaptoethanol (v/v). Chlorophyll and cellular debris were coagulated by the 
addition of butan-1-01 (O.8m1l10ml homogenate). Viral particles were precipitated 
using polyethylene glycol (4% w/v) and concentrated by centrifugation. The viral 
pellet was dissolved in 10mM pHS phosphate buffer. Virus yield was determined by 
measuring the absorbance at 260nm and assuming an extinction coefficient of 3. 
3.2.3.2 Recombinant TMV 
It was evident that the addition of the foreign V3 epitopes to the surface of TMV 
had altered its physiochemical properties. Specifically, the excess positive charge 
conferred by the V3 epitopes apparently made the recombinant CP/virions 











liquid nitrogen and resuspended in 60ml 50mM phosphate buffer, pH5 containing 
1 % 2-mercaptoethanol (v/v). The remainder of the protocol was carried and as in 
3.2.3(a) except that all phosphate buffers were used at pH5. 
3.2.4 Western blotting 
The procedure followed the methods set out in Appendix A(VIII) and A(IX), 
describing SDS-PAGE and immunoblotting. Blots were initially probed with a 
1/5000 dilution of rabbit anti-TMV CP specific polyclonal serum. 
3.2.5 Enzyme-linked immunosorbent assay (ELISA) 
ELiSAs were routinely carried out as described in Appendix A(X) for the detection 
of the V3-epitope peptide on the surface of recombinant TMVs. For this assay a V3 
peptide with the sequence N-(CTRPNNNTRKSIRIQRGPGRAFVTIGK 
IGNMRQAHCN)-C as well as a mouse-derived monoclonal antibody specific for 
the N-(KSIRI)-C sequence within each of the 151a, 151b, 179a and 179b epitopes 
was used at a 1/2000 dilution to establish a V3 peptide-specific standard curve. 
Both antibody and V3 peptide were acquired from the National Institute for 
Biological Standards and Control (UK; repository reference numbers EVA331 and 
ARP792.3 respectively). Detection of V3 peptide on the surface of recombinant 
TMV CPs required that the wells in the ELISA plate be coated with 1 O~g of each 
TMV CP recombinant and initially probed with a 1/2000 dilution of the above 
mouse V3-specific monoclonal antibody. This was followed by probing wells with a 












3.2.6 Electron microscopy 
3.2.6.1 Sample grid preparation 
Sample grids were analysed using the LEO 912 OMEGA Energy Filter 
Transmission Electron Microscope. Carbon coated copper grids were used for the 
visualisation of TMV extracts. Grids were applied carbon coated side down onto a 
15111 volume of undiluted TMV extract for 60 minutes. Grids were then washed 
twice by applying them on 15111 volumes of distilled water for 30 seconds per wash. 
Excess moisture was blotted from the grid between each wash. Grids were next 
stained with 2% uranyl acetate for 2 minutes, before excess stain was blotted from 
the grid. Grids were allowed to dry and stored in a grid holder. 
3.2.6.2 Antibody decoration 
Grids were applied carbon coated side down onto a 20111 volume of undiluted TMV 
extract for 60 minutes, then washed twice by applying them on 20111 volumes of 
phosphate buffered saline (PBS) for 1 minute per wash. Excess moisture was 
blotted from the grid between each wash. Grids were next blocked by applying 
them onto 20111 volumes of 1 % bovine serum albumin (BSA) in PBS for 30 minutes, 
and then washed as before. Grids were then probed with 1/500 dilution of either 
the anti-TMV or anti-V3 antibodies by applying grids onto the appropriate antibody 
dilution for 60 minutes, and next washed five times for 2 minutes each in distilled 
water as before. Grids were next stained with 2 % uranyl acetate for 2 minutes, 












3.3.1 In vitro transcription and inoculation of plants 
In vitro transcription reactions were successful in synthesizing the TMV RNA as 
indicated by the broad bands in Lanes 3, 5 and 7 in Figure 3.1. 






Figure 3.1 In vitro transcription reaction products are shown in Lanes 3, 5 and 7 
synthesized from their corresponding recombinant TMV based vector template DNA 
shown in Lanes 2, 4 and 6 respectively. Lane 1 contains the APSt DNA size marker. 
The in vitro synthesized RNAs were used for the inoculation of N. benthamiana 
plants using a leaf abrasion technique explained in 3.2.2. Each day post 
inoculation (dpi), N. benthamiana plants were observed for the development of the 
classic TMV infection symptoms, which included leaf curling, mottling, chlorosis, 
necrosis and/or growth stunting which is clearly distinct in comparison to a healthy, 











constructs initially manifested at 3-4 dpi in the uppermost leaves of the plant and 
subsequently spread to lower leaves, establishing a systemic symptomatic 
infection at 10 dpi. 
(a) 
Figure 3.2 (a) A healthy uninfected N. benthamiana plant displaying no ·rMV infection 
symptoms. (b) A N. bentham/ana plant that has been infected with one of the recombinant 
TMV constructs and displays leaf curling, mottling, chlorosis and a general stunting of 
growth indicated by the red arrows. 
Leaves were harvested from the inoculated plants at 10 dpi to ensure that an 
optimal yield in both leaf material and TMV particles was obtained. A longer 
infection period resulted in the rapid loss of exploitable leaf tissue as a result of 
severe systemic necrosis. 
3.3.2 TMV CP detection 
TMV CP was extracted from the harvested infected leaf material by means of 
optimised extraction protocols for either the wild-type CP (3.2.3.1) or the 
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Figure 3.3.1 Western blot of pLSB2296 TMV recombinants. Lane 1 molecular weight 
marker, Lane 2 pLSB2296 non-recombinant extract, Lane 3 pLSB2296+151a 
recombinant extract, Lane 4 pLSB2296+151 b recombinant extract, Lane 5 
pLSB2296+179a recombinant extract, Lane 6 pLSB2296+179b recombinant extract. 
Black arrows indicate the position of wild-type TMV CP monomers (+1-18kDa) and 
dimers (+/-36kDa), while the red arrows indicate the position of larger recombinant 
TMV CP monomers (+1-20kDa) and dimers (+/-40kDa). 
kDa 








Figure 3.3.2 Western blot of pLSB2109 TMV recombinants. Lane 1 molecular weight 
marker, Lane 2 pLSB2109 non-recombinant extract, Lane 3 pLSB2109+151a 
recombinant extract, Lane 4 pLSB2109+151b recombinant extract, Lane 5 
pLSB2109+179a recombinant extract, Lane 6 pLSB2109+179b recombinant extract. 
Black arrows indicate the position of wild-type TMV CP monomers (+1-18kDa) and 
dimers (+/-36kDa), while the red arrows indicate the position of larger recombinant 55 


















Figure 3.3.3 Western blot of pLSB2295 TMV recombinants. Lane 1 molecular weight 
marker, Lane 2 and 7 pLSB2295 non-recombinant extract, Lane 3 pLSB2295+151a 
recombinant extract, Lane 4 pLSB2295+151b recombinant extract, Lane 5 
pLSB2295+179a recombinant extract, Lane 6 pLSB2295+179b recombinant extract. 
Black arrows indicate the position of wild-type TMV CP monomers (+I-18kDa) and 
dimers (+1-36kDa), while the red arrows indicate the position of larger recombinant 
TMV CP monomers (+1-20kDa) and dimers (+/-40kDa). 
From the western blots (Figures 3.3.1-3) it is evident that the systemic spread of 
infection within the plants was accompanied by the expression and synthesis of 
recombinant TMV CP. It is evident that varying levels of expression occurred 
between the between the different constructs. The pLSB2296 recombinants 
(Figure 3.3.1) appear to exhibit the best results, as the recombinant CPs appeared 
as distinct 20 (monomer) and 40kDa (dimer) bands on the blot. These are 
indicated by the red arrows easily distinguished from the smaller wild-type bands 
indicated by the black arrows. None of the pLSB2296 recombinants (60S-loop) 
appeared to have reverted to a wild-type form, which indicates pLSB2296 
construct stability. The pLSB2109 recombinants (C-terminal, Figure 3.3.2) on the 
other hand, did not appear as stable; there was a distinct wild-type 18kDa 











(dimer) bands (red arrow) present in all pLSB2109 recombinant extracts. The 
pLSB2295 recombinants continually proved difficult to extract in significant 
quantities compared to the pLSB2109 and pLSB2296 recombinants. As seen on 
the blot in figure 3.3.3, recombinant bands were barely visible in comparison to the 
other 2 blots in which identical extraction volumes were loaded. It was also noted 
from this blot that wild-type CP bands are either not present or occur at much lower 
concentrations compared to the recombinant bands indicated by the red arrows, 
which may suggest that the N-terminal fusion in this vector interfered with TMV CP 
expression and drastically reduced expression levels. 
3.3.3 V3 Detection 
As a mere size difference between the wild-type and recombinant CPs was not 
sufficient to verify the presence of the V3 peptide on the surface of the 
recombinant TMV CPs, an immunoassay was employed to prove this. As identified 
in chapter 2 (2.3), the foreign peptide comprises approximately only 10% of the 
recombinant CP and the mOlJse antibody used to detect the V3 peptide is targeted 
towards a highly specific 5 amino acid sequence (N-KSIRI-C) that occurs within all 
variants of the peptide used. For this reason, high concentrations of recombinant 
TMV CPs were required for the detection of the V3 peptide. An ELISA was 
therefore employed instead for the detection of the V3 peptide on the TMV CP 
surface. To allow detection of the V3 peptide, 10l-lg amounts of each of the 12 
TMV recombinants were used to coat the ELISA plates, which were then probed 


























V3 Peptide Standard Curve 
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Figure 3.4 Standard curve for V3 peptide that shows homology to the V3 peptides 
displayed by the various constructs. Displayed on the graph is the formula for estimating 
the amount of V3 peptide between the ranges of 100ng to 1 ... g. 
V3 peptide detection ELISA 
1.2 








Figure 3.5 V3 detection ELISA results for the recombinant TMV vectors. Results of pLSB2295 
recombinant vectors are displayed in yellow, results of pLSB2109 recombinant vectors are 
displayed in blue, results of pLSB2296 recombinant vectors are displayed in pink and positive 
(1 ug V3 peptide) and negative (10ug wild-type TMV) control results are displayed in purple. All 













The formula generated by the V3 peptide standard curve (y = 4.073x - 0.2377) in 
figure 3.4 was used to calculate the levels of V3 peptide present in 10jJg of each 
recombinant CP from ELISA results (Figure 3.5). Results from the ELISA indicated 
that the V3 peptide is expressed by the recombinant virus, although at varying 
levels. As the foreign peptide occupied approximately 10% of the total recombinant 
CP, the V3 peptide levels were not expected to exceed 1 jJg/1 OjJg recombinant 
TMV CPo The pLSB2295, pLSB2109 and pLSB2296 recombinant CPs on average 
accumulated to approximately 75% (O.75jJg), 55% (0.55jJg) and 82% (0.82jJg) of 
this maximum value respectively. These varying levels of expression are found to 
correlate well with the western blot results (Figures 3.3.1, 2 and 3). As noted in the 
pLSB2295 and pLSB2296 western blots (Figure 3.3.1 and 3.3.3) only the larger 
recombinant CP monomer and dimer bands were distinctly visible, indirectly 
inferring a higher V3 peptide level compared to the pLSB2109 vector 
recombinants. In contrast the pLSB2109 western blot displayed a significant level 
of monomeric wild-type revertant CPs that has presumably lost the V3 peptide 
encoding sequence, which also correlates well with the low (+\-55%) levels of V3 
peptide generated by the pLSB2109 vector recombinants. The presence of the V3 
peptide on the surface of all recombinant TMVs was thus confirmed. 
3.3.4 Virion Assembly 
As a primary aim of this project was to produce a multivalent peptide presenting 
system, I investigated whether the recombinant CPs were capable of assembling 
into the highly repetitive, peptide-presenting virion structures. Recombinant TMV 
extracts were visualised by means of transmission electron microscopy and all 











polymeric rod like structures typical of TMV. Figure 3.6 (b), (c) and (d) illustrate the 
typical structures observed for each set of TMV recombinants, which appear 
identical to the non-recombinants (Figure 3.6 (a)). 
(a) (b) 
(c) (d) 
Figure 3.6 Transmission electron micrographs of TMV extracts displaying assembled virions. (a) 
plSB2109 non-recombinant, (b) plSB2109+151a recombinant, (c) plSB2296+151a recombinant, (d) 










As a means of visually confirming the presence of the V3 peptide on the surface of 
the assembled recombinant virions, the pLSB21 09+151 a extract was subjected to 
a V3 peptide-specific antibody decoration technique. If the V3 peptide is present on 
the surface of the assembled virion it would appear blurred by the presence of the 
V3 peptide-specific antibodies. The results shown in figures 3.7 (a), (b) and (c) 
verify the presence of the V3 peptide on the surface of the assembled 
pLSB21 09+151 a recombinant, as it appears with a shaded haze around the virion 
structures (Figure 3.7 (b», while the pLSB2109 non-recombinants clearly do not 
bind any of the V3 peptide-specific antibody (Figure 3.7 (a». In addition, the 
pLSB2109 non-recombinant vector is bound by the anti-TMV polyclonal serum 
(Figure 3.7 (c». This finally confirmed that the virions do assemble and display V3 












Figure 3.7 Transmission electron micrographs of V3 peptide and TMV specific antibody decorated TMV 
particles. (a) pLSB2109 non-recombinant extract probed with the V3 peptide-specific antibody, (b) 
pLSB2109+151a recombinant probed with the V3 peptide-specific antibody, (c) pLSB2109 non-













Several important points have been made in this chapter. The 3 types of 
recombinant vectors used were all shown to be proficient at initially infecting the 
inoculated plant and establishing a systemic infection, without excessively 
damaging the infected plant. This in turn has aided the extraction yield. Once 
plants were infected, the recombinant viral genomes expressed the recombinant 
viral CPs as seen in the western blots (Figures 3.3.1-3). The levels of expression 
and hence the recombinant CP yield from inoculated plants however, did vary 
depending on the vector used. The pLSB2295 (N-terminal fusion) vector 
recombinants gave the lowest CP yield. This observation is not completely 
unexpected, as it was shown that the TMV CP promoter extends into the CP ORF 
and thus the insertion 0 f a foreign sequence at the 5' end 0 f the CPO RF may 
interfere with expression by disrupting the promoter (Grdzelishvili et al., 2000). 
Furthermore, sequence deletion analysis by Grdzelishvili et al. (2000) has 
demonstrated that the core (minimal) promoter sequence lies between nucleotide-
69 and +12 from the CP open reading frame start position as opposed to the full 
promoter, which lies between -157 and +54 and which would allow maximal gene 
expression. Thus the low expression levels exhibited by the N-terminal CP fusions 
appears to be due to disruption of the CP promoter, which had significant effect on 
recombinant CP expression levels. Both the pLSB2296 (60S-loop) and pLSB2109 
(C-terminal) recombinants expressed higher levels of CP within the infected plants, 
which is also not unexpected as C-terminal CP fusions are most frequently used, 
and both fusions do not interfere with the promoter sequence (Fitchen et al., 1995; 











Wild-type CP revertants were observed for the pLSB2109 CP recombinants as 
demonstrated both in western blots and more accurately in the ELISA test, which 
showed lower (+/-55%) than expected V3 peptide levels contained in defined 
amounts of recombinant CPo This would render the pLSB2109 vector 
recombinants suboptimal choices for candidate vaccines as a result of the vector 
instability, when compared to the pLSB2296 (60S-loop) vector recombinants, 
which displayed an almost optimal level of recombinant CP and V3 peptide levels 
(+/-82%). 
Electron micrographs conclusively showed that the recombinant TMV CPs are 
capable of assembling into polyepitope-presenting virions, and that the foreign 
epitopes do not appear to Significantly sterically hinder virion assembly. The 
addition of the foreign epitope sequences to the T MV CP appears, however, to 
also have altered the physiochemical properties of the CP. Attention was first 
drawn to this fact by the observation that recombinant CPs were insoluble at the 
physiological pH7.4. This was theorised to have arisen due to the highly positive 
nature of the V3 peptides, which changed the overall charge of the TMV CP and 
required that the T MV extraction protocol be modified: I used buffers at pH5 to 
promote recombinant C P solubility. Similar insolubility problems have previously 
also been documented with recombinant TMV CP fusions in studies conducted by 
Fitchen et al., (1995) and Koo et al., (1999). The alteration in virion charge has 
previously also found to be associated with an increase in virion length up to 3 or 4 
times that of a wild-type virion (300nm) (Lu et al., 1996). This could account for the 
above electron micrographs of recombinant v irions that display a corresponding 











This chapter has demonstrated that T MV-based vectors have been synthesized 
that are capable of displaying multiple copies of the V3 peptide. They are thus 
suitable for testing in an animal model system to determine their immunogenicity 
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Immunogenicity analysis of proposed vaccine candidates usually requires the use 
of one or more animal models. Generally, animal models are selected based on 
the purpose of the proposed vaccine, although several other physical factors also 
play key roles in helping to select an animal model for immunogenicity analysis. 
These factors may include the required animal cohort size, space, time and 
financial restrictions; thus, the selection of an animal model requires significant 
forethought. Furthermore, the selected animal model has direct bearing on the 
possible methods (route) of vaccine administration and hence the desired type of 
immune response. 
Typically, vaccine immunogenicity analysis has utilized either primate (baboon, 
macaque, chimpanzee) or small animal (mouse, rabbit, rat, guinea pig) animal 
model systems (Letvin et aI., 2001; Marusic et al., 2001; Staczek et al., 2000, Liao 
et al., 2000 and 2004; Oscherwitz et al., 1999). Small animal models are 
comparatively more simplistic as they occupy less space, require smaller inoculum 
doses and are overall easier and more cost-effective to maintain. Primate models 
on the other hand, present a system that more closely resembles that for which the 
vaccine is intended, when developing a vaccine for human purposes. It is therefore 
assumed that primate a nimal models would be the better option when testing a 
proposed HIV vaccine. Despite this, several proposed HIV vaccines have 
generated promising immune responses within small animal model systems 












The "newer" generation of experimental vaccines have often been composed of 
synthetic, recombinant, or highly purified peptide subunit antigens and rely on this 
fact to stimulate highly specific immune responses (Fitchen at al., 1995; Durrani at 
a/., 1998., Oscherwitz at a/., 1999; Staczec at a/., 2000; Liao et al., 2000 and 
2004). In comparison, whole-killed and live-attenuated vaccines, which are not 
deemed safe as they pose the threat of reverting to a wild-type form, elicit broader 
and possibly more non-specific immune responses. Purified subunit vaccines, 
however, are known to stimulate weaker, localized immune responses as they lack 
the immunomodulatory (enhancing) components associated with whole-killed and 
live-attenuated vaccines (www.niaid.nih.gov/daids/vacine/adjuvants/htm). 
Immunostimulatory (enhancing) compounds or adjuvants are therefore often 
administered in conjunction with these subunit vaccines. Adjuvants are defined as 
compounds that can enhance the immune response to a particular antigen when 
incorporated into the inoculum. Adjuvants encourage prolonged immune 
responses by allowing the slow or intermittent release of antigen from the site of 
inoculation, which otherwise would be rapidly cleared from the inoculation site. 
Adjuvants also assist with delivering the antigen to antigen-presenting cells (APes) 
in the spleen and lymph nodes where most necessary antigen processing occurs, 
and most necessary cell-cell interactions occur for the generation of plasma cells. 
A third mechanism by which adjuvants enhance immune responses is by activating 
various cells involved in the immune response by means of surfactants. 
Surfactants commonly constitute one or more components of all adjuvants and 
usually consist of bacteria, bacterial products or derivatives of bacterial products 
(www.nal.usda.gov.awic/pubs/antibody/overview.htm). Thus depending on the 











There are currently several different types of adjuvants in use for animal 
immunogenicity analysis which are able to stimulate different parts of the immune 
system (www.naLusda.gov.awic/pubs/antibody/overview.htm). Freund's complete 
adjuvant (FCA) and Freund's incomplete adjuvant (FIA) appear to be the most 
frequently used adjuvants. FCA is primarily composed of a water and mineral oil 
emulsion containing killed mycobacteria. FCA is known to cause severe chronic 
inflammatory responses at the site of inoculation, which may cause pain and 
discomfort to the inoculated animal (www.naLusda.gov.awic/pubs/ 
antibody/overview.htm). FIA is identical in composition to FCA except lacks killed 
mycobacteria, and consequently causes inflammatory reactions which are much 
less severe than FCA (www.naLusda.gov.awiclpubs/antibody/overview.htm). FIA is 
also known to favour humoral immune responses without any cell mediated 
immune responses, which made it ideal for my purposes in this study 
(www.nal.usda.gov.awic/pubs/antibody/overview.htm). 
Vaccine delivery can potentially occur via a number of different routes, and each 
route has previously been used to elicit a desired immune response. Oral, nasal or 
rectal delivery of a vaccine has been shown to stimulate mucosal immune 
responses (Awram et a/., 2002; Koo et aI., 1999; Marusic et aI., 2001; Durrani et 
al., 1998), while direct inoculation of animals subcutaneously, intramuscularly or 
intradermally is known to stimulate more generalized systemic immune responses 
(Liao et al., 2004 and 2000; Letvin et al., 2001 ; Staczek et aI., 2000; Koo et aI., 
1999; Joelsen et al., 1997). For HIV it is most desirable to stimulate a disseminated 
mucosal immune response, as mucosal surfaces in the genital regions are the 











(cellular/humoral) immune responses would also be desired to complete the barrier 
of protection against HIV infection. 
In this chapter the core objectives of this project were investigated. Are the 
recombinant TMV particles immunogenic and capable of stimulating a V3 peptide-
specific humoral immune response? Of greater significance, is whether a V3 
peptide-specific response is observed; will the serum of inoculated animals display 
an ability to neutralize an HIV infection? Guinea pigs were selected as the animal 
of choice in these experiments as their sera contain lower levels of background 
HIV-1 NAb activity (personal communication, Dr David Montefiori; Liao et al., 2000; 
Zhu et al., 2003; Liao et al., 2004; Gao et al., 2005). Thus, selected TMV 
recombinants were inoculated subcutaneously in conjunction with Freund's 
incomplete adjuvant into guinea pigs and serum extracted from these animals was 
tested for the desired responses. 
As a result of time constraints not all recombinant TMV constructs were assessed 
for their ability to stimUlate an immune response in the selected guinea pig model. 
Thus, only the pLSB2109+151a (100l-lg/site TMV), pLSB2109+151b (100I-lg/site 
TMV) and a combination of pLSB2109+151a (50I-lg/site TMV) and 
pLSB21 09+151 b (50IJg/site TMV) recombinant TMV constructs were assessed for 
their ability to stimulate an anti-V3 peptide response and compared to the 
pLSB2109 non-recombinants. Although it does seem contradictory to use this 
particular construct in light of what has been discussed in chapter 3, the selection 
of this recombinant vector was determined before the actual quantitive data in 











4.2 MA"rERIALS AND METHODS 
The Dunkin Healy strain of guinea pigs was used in all immunization experiments. 
All guinea pigs used were female and averaged between 500g and 600g in weight. 
4.2.1 Guinea pig inoculation procedure and schedule 
Four sets of guinea pigs were immunized with different TMV constructs and each 
set consisted of four guinea pigs. Each animal was injected subcutaneously at 4 
sites along the neck and lumbar regions with 100ug/site of a 50% volume/volume 
mixture of Freund's incomplete adjuvant (Sigma-Aldrich) and TMV preparation in a 
phosphate buffer (PBS). The guinea pigs were inoculated at 4 week intervals and 
bled under anaesthesia (65% (100mg/ml) Ketamine + 35% (2%) Rompun mixture) 
via cardiac bleed yielding 4 - 5 ml blood/500g guinea pig prior to each inoculation. 
Effectiveness of the anaesthetic was evaluated by checking the pedal and eye 
rel1exes of the animal before attempting the cardiac bleed. Serum was separated 
from the cellular constituents in the blood by centrifuging the blood samples at 
3000g for 15 minutes. Serum samples were stored at 4 aC. 
4.2.2 V3 peptide-specific serum ELISA 
ELiSAs were conducted according to the protocol outlined in Appendix A(IX). 
Initially, ELISA plates were coated with 100ng of a V3 peptide per well. I used the 
same V3 peptide as the ELISA described in 3.2.5 I.e. N-
(CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHCN)-C. Plates were probed 
overnight with a 1/100 dilution of serum from inoculated guinea pigs. Presence of 











with a 1/10000 dilution of alkaline phosphatase conjugated goat anti-guinea pig 
secondary antibody (Sigma-Aldrich). 
4.2.3 HIV Neutralization assays 
As a result of the complexity, lack of facilities, required equipment and expertise 
required to conduct the neutralization assay, at my current institution (UCT) I could 
not conduct the assay personally. Neutralization assays were therefore conducted 
by Natasha Taylor at the National Institute for Communicable Diseases, 
Johannesburg, South Africa. Serum samples from immunized animals were tested 
for neutralizing antibody activity using a single cycle recombinant pseudovirus 
assay (Montefiori., 2004). This assay measures neutralization as a function of a 
reduction in luciferase reporter-gene expression in HeLa-derived TZM-bl indicator 
cell line. This cell line expresses high levels of CD4 and CCR5 along with 
endogenously expressed CXCR4. Luciferase activity is quantified by luminescence 
and is directly proportional to the number of infectious pseudoviruses (Du151) 
infecting TZM-bl cells. 
Serum samples from 4 guinea pigs (animals' no. 712, 725, 772, 791) at three time 
points were selected (pre-bleed and 1st and 2nd bleed serum samples). Samples 
were heat-inactivated at 56° C for 15 minutes. Assays were conducted in flat-
bottomed 96 well microtitre plates. One hundred microlitres of Dulbecco's modified 
Eagles medium +10% fetal calf serum (Growth medium/GM) was added to each 
well. Each serum sample (221-11) was t hen added in triplicate tot he wells 0 f the 
microtitre plate as 1/10, 1/30, 1190, 1/270 dilutions. Fifty microlitres of the test virus 











incubated at 3rC in a humidified incubator for 1 hour. One hundred microlitres of 
the TZM-bl target cells to be infected were then added (1x104/well) to each well. 
Plates were then incubated at 3rC in 5% CO2 for 48 hours. One hundred and fifty 
microlitres 0 f culture medium was then discarded from each well. Following this 
1001-11 of Bright GloTM reagent was dispensed into each well and plates were 
incubated at room temperature for 2 minutes to allow complete cell lysis. Contents 
of each well were mixed by pipette action (two strokes) and 1501-11 transferred to a 
corresponding 96-well black plate. Luminescence was then read from the plate 
immediately in a luminometer. The 50% infectious dose (I050) was then calculated 
(the reciprocal dilution where 50% of the virus is neutralized by the serum sample). 
Wells with RLU <2.5 times background were considered negative for the 
calculation. 
A positive control was run on each plate. The positive control used was IBU-21, 
which is a plasma sample 'from an HIV-1 infected individual with a high titre of 
neutralizing antibodies. This reaction consisted of 45ul GM plus 5ul IBU-21 in 
triplicate. For this control a series of 4, 3-fold dilutions, 1/45, 1/135, 1/405, 1/1215 
was made. The no virus, cell control consisted of only 1501-11 GM with 1001-11 of 
TZM-bl cells (1x104/well). The serum free, virus control was made up identically to 












4.3.1 V3-specific Serum Response assay 
V3 peptide-specific serum ELiSAs all indicated that a V3 peptide-directed immune 
response was stimulated by the inoculated recombinant TMV constructs (Figures 
4.1, 4.2, and 4.3). Serum extracted from the pLSB2109 non-recombinant 
inoculated guinea pigs all displayed very similar results and thus as a point of 
reference absorbance readings were averaged and displayed on each of the 
graphs below to serve as the negative control. As some serum samples reacted 
very strongly in the ELISA a maximum absorbance cut-off of 2 ODU was set to 
allow comparisons between the various serum samples. It was evident that pre-
bleed serum samples extracted before the first inoculation. as well as all serum 
extracted from guinea pigs inoculated with the non-recombinant TMV constructs, 
all displayed only background level reactions and thus did not display any V3 
peptide-specific immune responses (Figures 4.1,4.2, and 4.3). The V3 peptide-
specific immune responses were found to noticeably increase after each boost and 
demonstrated the strongest response at the second bleed stage (Figures 4.1, 4.2, 
and 4.3). 
Serum extracted from guinea pigs inoculated with the pLSB2109+151a 
recombinant construct did not display uniform V3 peptide-specific immune 
responses (Figure 4.1). Results were found to vary considerably between guinea 
pigs, and serum from guinea pigs 771 and 773 only displayed relatively significant 
reactions for the second bleed, while prior samples displayed reactions 











immunocompromised as they had diarrhoea, which may have caused the weaker 
V3 peptide-specific serum response. V3 peptide-specific responses in the serum 
extracted from guinea pigs 770 and 772 on the other hand were clearly stronger 
than those displayed in 771 and 773. 
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. 2rd Bleed 
Figure 4.1 V3 peptide-specific ELISA result for serum isolated from guinea pigs 770, 771, 772 
and 773 at pre-bleed, 1st·bleed and 2nd-bleed stages relative to inoculation with the 
pLSB2109+151a TMV recombinant. For comparative purposes the average result for sera 
isolated from guinea pigs inoculated with the pLSB2109 non·recombinants is displayed. 
Sera extracted from the pLSB21 09+151 b recombinant construct-inoculated guinea 
pigs displayed more uniform set V3 peptide-specific immune responses with no 
particular guinea pig's serum extraction displaying an exceedingly positive or 











clearly indicates that the desired V3 peptide-specific immune response has been 
stimulated. 
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Glinea pig 711 Glinea pig 712 Guinea pig 768 Guinea pig 769 Non recombinart 
average 
Figure 4.2 V3 peptide-specific ELISA result for serum isolated from guinea pigs 711, 712, 
768 and 769 at pre-bleed, 1st-bleed and 2"d-bleed stages relative to inoculation with the 
pLSB2109+151b TMV recombinant. For comparative purposes the average result for sera 
isolated from guinea pigs inoculated with the pLSB2109 non-recombinant is displayed. 
Similar to the serum extracted from the pLSB21 09+151 b inoculated guinea pigs, 
the sera extracted from guinea pigs inoculated with both pLSB21 09+151 a and 
pLSB21 09+151 b recombinants give uniform results with no particular serum 
extraction displaying an exceedingly positive or negative result (Figure 4.3). A V3 
peptide-specific immune response was nevertheless observed for all of this 











from guinea pig 725 in particular displayed the strongest V3 peptide-specific 
immune response. 
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Figure 4.3 V3 peptide-specific ELISA result for serum isolated from guinea pigs 723, 725, 
796 and 799 at pre-bleed, 1st-bleed and 2nd-bleed stages relative to inoculation with the 
pLSB2109+151a and pLSB2109+151b TMV recombinants. For comparative purposes the 
average result for sera isolated from guinea pigs inoculated with the pLSB2109 non-
recombinants is displayed. 
4.3.2 Serum Neutralization Assays 
To assess whether the serum that displayed the V3 peptide-specific immune 
responses was capable of neutralizing an HIV infection, serum samples that 
displayed the strongest responses in the ELiSAs were used in HIV neutralization 
assays. Serum extracted from guinea pigs 772, 712 and 725 were tested for the 
ability of the pLSB2109+151a, pLSB2109+151b and pLSB2109+151a and 151b 

















a guinea pig (791) inoculated with the pLSB2109 non-recombinant was tested to 
serve as a negative control. 
The selected serum samples were all subjected to an HIV neutralization assay in 
replicate, but despite the observed V3 peptide-specific activity none of the serum 
samples displayed an ability to neutralize HIV-1 infection (Figures 4.4(a) and (b}). 
All tested serum samples thus displayed results indistinguishable from observed 
background activity observed for the negative control (791) (Figure 4.4(a» and 
incomparable to results generated by the positive controls. 
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Figure 4.4. Neutralization assay results, (a) results for serum extracted from guinea pigs 772 and 791 
inoculated with pLSB2109+151a and the pLSB2109 non-recombinant respectively at the pre-bleed, 
1st bleed and 200 bleed stages, (b) results for serum extracted from guinea pigs 712 and 725 
inoculated with pLSB2109+151b and the pLSB2109+151a and 151b at the pre-bleed, 1st bleed and 2nd 
bleed stages. 
The positive control, IBU-21 (serum sample with high titre of neutralizing 
antibodies) as expected showed inhibition of viral infection that decreased as the 











(indicated by solid black line) were 1: 515 and 1: 599 for the 2 positive controls run 
on each plate which is within the acceptable range. None of the guinea pig serum 
samples therefore showed any neutralization activity. The low level neutralization 
activity seen in the pre-bleed of guinea pig 712 is most likely toxicity of serum at 












The concluding component of this study encountered both its share of success and 
failure in relation to the immunological analyses. The first important point is 
highlighted by the fact that the recombinant TMV-derived vector was capable of 
stimulating and efficiently targeting a desired immune response to the foreign 
protein. This was evinced by the strong V3-specific immune response stimulated in 
the inoculated guinea pigs. On average, immune responses stimulated by the 
different recombinant vectors did not vary much and the overall strong V3-specific 
immune responses could be attributed to the effective means of epitope 
presentation by each of the TMV-based vectors. Variations in the immune 
responses did occur though, notably with the pLSB2295 recombinant vector. 
Moreover, weakened V3-specific immune responses could be attributed primarily 
to the health of the guinea pig. some of which were possibly immunocompromised 
(771.773). 
Despite the strong V3-specific immune responses observed in the serum of 
inoculated guinea pigs, these can be regarded as ineffectual, as the stimulated 
immune responses did not confer any HIV neutralization activity. As observed in 
figures 4.4(a) and (b) none of the serum samples generated results that could be 
distinguished from the negative control (serum extracted from guinea pig 
inoculated with the pLSB2109 non-recombinant). A number of reasons could be 
presented for the failure to neutralize the Du151 derived pseudovirus infection of 
target cells in the neutralization assay. Popular consensus suggests that the 
Du151 primary isolate from which the pseudovirus was derived, aided in the failed 











on the envelope glycoproteins of primary isolates can be inaccessible for antibody 
binding (Beddows et a/., 1998; Spenlehauer et al., 1998, Letvin et a/., 2001; Parren 
et a/., 1998; Zhu et a/., 2003; Gorny et a/., 1998). Hence V3-specific antibodies 
have been inconsistent in their neutralization of primary isolates. This may seem 
contradictory as the Du151 primary isolate-derived V3 epitope used was selected 
as a result of the broad cross-neutralizing activity displayed in the infected 
individual. Letvin et al., (2001) has demonstrated similarly in SHIV models that V3 
in some primary isolates may only be a partially effective target for neutralizing 
antibodies induced by peptide immunogens compared to other primary isolates. 
The context in which the V3 epitope was presented to the immune system may 
also have contributed to the neutralization failure. The linear V3 epitope displayed 
by the recombinant TMV could have stimulated an inferior neutralization response 
as compared to the native three dimensional structure of the V3 loop. The display 
of T-helper epitopes has been shown to affect the overall immunogenicity of an 
epitope (Grudner et a/., 2004). The three dimensional positioning of the T-helper 
epitopes within the native gp120 may therefore have affected antigen processing. 
As described earlier, the binding of anti-V3 antibodies is most effective when the 
V3 domain retains its conformation and with respect to this the strength of binding 
of anti-V3 antibodies to HIV virions has been shown to correlate with neutralizing 
activity, which has also been described for other epitopes (Schreiber et al., 1997; 
Krachmarov et a/" 2001; Gorny et al" 2002; Burrati et al., 1998; Taylor et al., 
2000). 
Traditionally the strength of an immune response has not always been reflective of 











immune responses have been displayed in studies investigating the ability of C4-
V3 chimaeras to neutralize an SHIV infection (Letvin et al., 2001; Liao et al., 2000). 
C4-V3 chimaeras displaying V3 peptide derived from SHIV89.6 or 89.6P were 
used to immunize a nimals and serum samples were assayed f or V 3-specific as 
well as neutralizing antibody activity. Both SHIV89.6 and 89.6P derived C4-V3 
constructs elicited strong V3-specific serum antibody responses. Antibody 
responses generated by the SHIV89.6 C4-V3 fusions were capable of stimulating 
antibody levels capable of recognising both 89.6-V3 and 89.6P-V3. While the V3-
specific antibodies generated by the SHIV89.6 C4-V3 fusions neutralized SHIV-
89.6 but not SHIV-89.6P despite the fact that V3-specific antibodies recognised 
both viruses equally well. Immunization with the SHIV89.6P on the other hand 
generated antibodies capable of neutralizing both SHIV89.6 and SHIV89.6P. 
Although the magnitude of SHIV89.6 neutralization exceeded the neutralization of 
89.6P. These observations suggest that the V3 loop on some primary patient HIV-
1 isolates may only be a partially effective target for neutralizing antibodies induced 
by peptide immunogens and would seek to discredit the notion that the antibody 
response generated by the TMV chimaeras failed to neutralize HIV pseudovirion 
activity as a result of an overall weak immune response. 
Possibly an alternative means of epitope display would be better suited to the 
display of V3. One such display system utilises the Alfalfa mosaic virus CP on a 
TMV based backbone, which has allowed for the insertion of much larger epitopes 
than can be accommodated by the TMV CP (Yusibov et al., 1997). T his vector 
system which still utilises the TMV mechanism of gene expression would therefore 











response in infected individuals. It may also be possible therefore that an 
unidentified region of V3 on primary isolates, which remains exposed for the initial 














Now, more than ever, there is a pressing need for the development of a 
protective/preventative measure against HIV infection. Infection rates, particularly 
in sub-Saharan Africa, have reached colossal proportions and are still accelerating. 
Internationally, billions of dollars are invested/required each year for antiretroviral 
treatment of infected individuals with a projected need of US $2.8 billion dollars 
required for 2005 to negate the further spread of infection 
(http://www.who.intl3by5/progressreport05/enD. The recent tsunami that struck 
South-East Asia in December 2004 has killed in excess of 200000 people and has 
resulted in one of the largest international humanitarian efforts. Countries have 
collectively pledged in excess of US $4 billion for this disaster, and despite this, the 
mobilisation of funds for purposes of HIV treatment or research which on average 
has the potential to save a far greater number of people, has not received such 
wide appeal for funding. 
Currently in developing countries the lowest price for the treatment of a single 
infected individual is around US $140 per person per year, but average prices are 
at least US $300 (http://www.who. intl3by5/progressreport05/enD. This is not good 
news as the poorest countries concentrated in sub-Saharan Africa and South-East 
Asia appear to be affected the worst by the AIDS pandemic. As these countries are 
not likely to cope financially with the treatment of infected individuals without 











antiretroviral treatment. It has also become apparent that investment in HIV 
infection prevention (vaccines) should ultimately be more sensible and cost 
effective than the partially effective antiretroviral treatment of infected individuals 
currently used. This study therefore does not dispute the importance of continued 
antiretroviral therapy, but does support the use of an alternative, protective 
strategy against HIV infection. 
The requirement for a n alternative, cost-effective means of treatment (vaccines) 
has advocated the use of plants as bioreactors. Plants used in concert with 
recombinant plant viral vectors, have the potential to greatly reduce the costs of 
raw materials, eliminate the requirement for highly specialized facilities and can be 
rapidly scaled-up to produce large quantities of the desired product. Today the use 
of plants also appears to have greater social appeal and encounters greater social 
acceptance as it would not harbour any human pathogens. 
This project has successfully yielded a polymeric epitope display system utilising a 
set of TMV-based expression vectors. Vectors successfully displayed the HIV-1 
subtype C V3 epitope at either the N-terminus, C-terminus or 60S-loop positions of 
the TMV CPo The assembled virions in turn, displayed the foreign epitopes at their 
surface, which changed the physiochemical properties and predicted size 0 f t he 
virus. Despite the physiochemical alterations to the a ssembled virion (increased 
virion length and coat protein charge), plants infected with the recombinants 
showed leaf shrivelling and growth stunting symptoms similar to that of wt TMV 
and similarly did not cause excessive necrosis in the infected plant hence yielded 











position at which the foreign epitope was inserted in the coat protein. Insertion of 
the V3 epitopes into the 60S-loop position generated the most stable and abundant 
recombinant CPo N-terminal insertions interfered with expression levels and the C-
terminal insertions generated unstable CP recombinants that reverted to a wt TMV 
form. 
Immunogenicity of the C-terminal CP recombinants was assessed in a guinea pig 
animal model. All recombinant vectors inoculated into guinea pigs stimulated a 
strong V3-specific serum antibody response successfully. This indicated that the 
recombinant vectors were effective at displaying the foreign epitope to the immune 
system and enabled a targeted immune response towards the V3 epitope. Serum 
extracted from t he inoculated guinea pigs was tested f or any H IV neutralization 
activity utilising a primary isolate-derived pseudovirus, but unfortunately none of 
the serum samples even at a low serum dilution exhibited any neutralization 
activity. As discussed previously a number of reasons could have accounted for 
this. This barrier to HIV primary isolate neutralization has been encountered in 
several other studies, which prompts further studies with respect to the barriers of 
primary isolate neutralization (Letvin et al., 2001; Zhu et al., 2003; Messer et al., 
2004). The complete absence of neutralization activity clearly challenges 
reasoning for using the Du151-derived V3 epitope which as discussed was chosen 
as a result of the broad cross-neutralizing activity displayed in the infected 
individual. A study in which V3-specific immune responses were only found to be 
partially effective against some primary isolates has suggested that protection 
against viral challenge may be conferred by an antibody activity other than 











vivo may arise from a barely detectable NAb, which is diluted during in vitro 
analyses. Non-NAbs analysed using the Friend retrovirus have been shown to aid 
an immune response and thus should not be discredited (Messer at al., 2004). 
Passive transfer of non-NAbs along with NAbs to 8-cell deficient mice was found to 
stimulate a far superior response compared to the transfer of the NAbs alone. The 
enhanced immunogenicity is likely a result of an additional cellular immune 
responses promoted by the non-NAbs. It is also therefore realised that the 
stimulation of both a humoral as well as a cellular immune response is necessary 
to effectively neutralize an HIV infection. In the Friend retrovirus model vaccine 
primed T -cells were found to work synergistically with NAbs to provide a level of 
protection greater than that provided by either NAbs or T-cells alone (Messer at al., 
2004). 
To conclude, it is clearly evident that the TMV-based vector system used was 
highly successful in its ability to stimulate a strong immune response towards the 
foreign epitope it presented. The problem encountered was that the stimulated 
response did not include the desired ability to neutralize an HIV infection and for 
this the particular selected V3 epitope could be held accountable. This suggests 
that if an appropriate HIV envelope protein epitope were selected, the TMV-based 
vector system could still prove useful and this study would h ave paved a direct 
path towards the development of variants of my recombinants. The applications of 
this vector also extends beyond HIV vaccine development and could be used for 
the presentation of epitopes derived from other disease-causing organisms such 












HIV research, and in particular the development of a protective vaccine has 
become one of the biggest, most well-funded and ambitious endeavours that the 
international scientific community has ever embarked on. Unlike many other 
vaccine types the HIV vaccine has proven highly elusive as the virus has 
surpassed all preconceived notions as to its abilities and with that every strategy 
we have employed to eradicate it. Hence the continued research into all aspects of 
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I. Bacterial growth media, conditions, antibiotics and strains 
All bacterial cultures were grown in Luria-Bertani (LB) broth (5g bacto-tryptone, 5g 
yeast extract, 10g NaCI, 950ml distilled H20, pH adjusted to 7.4 using NaOH, 
made up to 1 Land autoclaved. 
Luria-Bertani agar was made up with the same constituents as LB, but also 
contained 15g agar/L. 
Ampicillin was used as a selective marker at 100j.lg/ml concentrations in both LB 
media and Luria agar to select for the ampicillin-resistant clones. 
Liquid cultures were all grown at 37°C with agitation. 
The DH5a strain of E.coli (Invitrogen) was used for the transformation of DNA. 
II. DNA extraction procedures 
a. Small-scale plasmid DNA extraction 
DNA was isolated from 5ml overnight bacterial cultures according to the protocol of 
the QIAprep Spin Miniprep Kit (Qiagen), which is based on the alkaline hydrolysis 
technique of Sambrook et al. (1998). 
b. Large-scale plasmid DNA isolation 
DNA was isolated from 1 OOml overnight bacterial cultures using and carried out 
according to the protocol of the Qiagen Plasmid Midi Kit (Qiagen), which is based 











III. Shrimp alkaline phosphatase DNA treatment 
Restriction enzyme-digested DNA was treated with 1 u/1l1 of Shrimp Alkaline 
Phosphate (Roche) for 30 minutes at 37°C, and the reaction was terminated by 
incubation at 65°C for 10 minutes to remove 5'-phosphate groups to prevent vector 
self-I igation. 
IV. Agarose gel electrophoresis of DNA and RNA 
Gel electrophoresis of both DNA and RNA was carried out using 1 % agarose gels 
containing 0.5Ilg/ml of ethidium bromide in a 1 x Tris-borate EDTA buffer at 95 
volts. DNA fragment size was estimated using a A-DNA marker digested with Pst! 
giving a size estimation range of between 11497bp and 15bp. For RNA gels, all 
reagents were prepared under RNase free conditions. 
V. Gel and endonuclease reaction purification of DNA 
Purification of DNA from agarose gels or directly from endonuclease reactions to 
remove undesired buffers and enzymes was carried out using the Amersham 
Biosciences DNA purification kit. To isolate specific DNA fragments derived from 
endonuclease reactions, the DNA was loaded onto a 1 % agarose gel containing 
0.5Ilg/ml ethidium bromide and electrophoresed at 95 volts. The bands of interest 
were visualized on a UV transilluminator plate (310nm) and excised using a sterile 
scalpel blade. The excised gel slice was placed into a 1.5ml eppendorf tube and 













DH5a E. coli cells were made competent and transformation was carried out using 
the method of Chung and Miller. (1989). Transformations using 100111 of competent 
cells with 2111 of pGEM®-T Easy (Promega) ligation reaction DNA or 50119 of DNA 
was conducted. The DNA and competent cells were mixed in a 1.5 ml eppendorf 
tube and chilled on ice for 30 minutes. The cells were then heat-shocked at 37°C 
for 25 seconds, followed by incubation on ice for 2 minutes. 700JlI of LB was then 
added to the transformation mix, which was then incubated at 37°C for 1 hour 30 
minutes. 100111 volumes of each transformation mix was then plated on Luria agar 
plates containing 100 Ilg/ml ampicillin as a selective marker. Transformants were 
plated on Luria agar plates that also contained 800111 (10%) Xgal and 2ml (0.1 M) 
IPTG/400ml Luria agar. 
VII. DNA sequencing 
Purified miniprep DNA was used for the sequencing reactions by means of a 
technique derived form the dideoxy chain terminating method of Sanger et at. 
(1977). This service was provided by the Department of Molecular and Cell 
Biology's DNA sequencing service, University of Cape Town, Cape Town, South 
Africa, which used the Thermosequence ™ cycle sequencing kit (Amersham 
Biosciences) and reaction products analyzed on an ALF-Express ™ DNA 
Sequencer version AMV2.0 (Pharmacia Biotech). Analysis of the generated 
sequences was done using the DNAMAN program for Windows version 4.13 











Sequencing primers used: 
For pGEM-T® Easy - pUC/M 13 Primer, Forward (24mer) (Promega) 
For pLSB vectors -TMV coat protein forward: 5' AGG CTA CTG TCG CCG MT 3' 
- TMV coat protein reverse: 5' GCG TT A TCG TAC GCA CCA 3' 
VIII. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out as described by Laemmli. (1970). Approximately 
1.5mm thick gels comprised of a 15% resolving gel and a 4% stacking gel were 
poured into a Hoeffer SE-600 vertical slab gel apparatus (Hoeffer Scientific 
Instruments). Samples to be electrophoresed were denatured by mixing with an 
equal volume of protein loading buffer (10% [w/v] SDS, 15% glycerol, 15% 2-
mercaptoethanol, 0.01 % bromophenol blue, 0.125M Tris-HCI pH6.8) and heating 
to 100°C for 10 minutes. Electrophoresis was carried out at 20mAlgei until the dye 
front reached the bottom of the gel. Gels were stained with 0.2% (w/v) PAGE blue 
83 (BDH chemicals) dissolved in a 45:45:10 (v/v) mixture of methanol, water and 
glacial acetic acid. Stained gels were destained with a destain solution consisting 
of 65:25:10 (v/v) mixture of methanol, water and acetic acid. 
IX. Western Blot 
Protein from SDS-PAGE gels was transferred onto nitrocellulose membranes 
(Hybond) using a semi-dry blotting electroblotter (BioRad™}. Blotting was carried 
out for 40 minutes at 15 volts, after which membranes were blocked for 30 minutes 
at room temperature in a 1 % Tween-20, 5% milk powder in phosphate buffered 
saline solution. Depending on the type of blot, membranes were next probed 











subsequently washed with blocking buffer 4 X for 15 minutes/wash before being 
probed with an appropriate dilution of alkaline phosphatase conjugated secondary 
antibody (Sigma-Aldrich) for 2 hours at room temperature. The blots were next 
washed with blocking buffer lacking milk powder a s above. 0 etection was v ia a 
colorimetric reaction using the SIGMAFASfTM , 5-Bromo-4-chloro-3-indolyl 
phosphate/Nitro blue tetrazolium (BCIP/NBT) containing tablets as per supplier's 
directions (Sigma-Aldrich). 
X. Direct ELISA 
The direct ELISA protocol is based on the technique of Ausubel et al. 1994. One 
hundred microlitre volumes of relevant protein samples were used to coat 96 well 
Maxisorp® ELISA plates (Nunc), which were then incubated overnight at 4°C. 
Plates were washed 3x using 300111 PBS per well with an ELISA plate washer 
(Titretek® Microplate washer S8/12). Two hundred microlitres of blocking buffer 
(Appendix A(IX)) was added to each well and incubated for 2 hours at room 
temperature. Plates were then washed 3x using 300111 PBS per well. Plates were 
probed overnight at 4°C with appropriate dilutions of protein-specific primary 
antibodies diluted in blocking buffer. Plates were then washed 3x using 300111 PBS 
per well. One hundred microlitre volumes of a 1/10000 dilution of an alkaline 
phosphatase-conjugated secondary antibody diluted in PBS containing 3% BSA 
was added to each well and incubated at 37°C for 2 hours. Plates were washed 3x 
IJsing 300111 PBS per well. One hundred microlitres of p-nitrophenyl phosphate 
(PNPP) substrate (1 mg/ml), made fresh using SIGMA FASTTM p-nitrophenyl tablet 











405nm using the Titretek Multiskan® Plus MKII ELISA plate reader 2 hours after 
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Figure 81 The pGEM®-T -easy cloning vector (Promega) used for the cloning of the V3-loop 












NgoMIV (6213) ---.". 
NcoI (6201) 
TMV coat protein 
pLSB2109 
9158bp 
Figure B2 pLSB2109 TMV based vector provided by LSBC, which contains the 
NgoMIVI Ncol cloning site at the C-tenninus of the TMV coat protein. 
(3) pLSB2109 coat protein sequence 
Translation of pLSB2109(1-519) 
Total amino acid number: 172, MW=19075 
Max ORF starts at AA pos 1 (may be DNA pos 1) for 172 AA(516 bases), 
MW=19075 
1 ATGTCTTACAGTATCACTACTCCATCTCAGTTCGTGTTCTTGTCATCAGCGTGGGCCGAC 
1 M S Y SIT T P S Q F V F L S SAW A D 
61 CCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAAACACAACAA 
21 PIE LIN L C T N A L G N Q F Q T Q Q 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTTCCCTGACAGTGACTTTAAGGTGTACAGGTACAATGCGGTATTAGACCCGCTA 
61 V R F P D S D F K V Y R Y N A V L D P L 
241 GTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTTGAAAATCAG 
81 V TAL L G A F D T R N R I I EVE N Q 
301 GCGAACCCCACGACTGCCGAGACGTTAGATGCTACTCGTAGAGTAGACGACGCAACGGTG 
101 A N P T T A E T L D A T R R V D D A T V 
361 GCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGAT CAGAGGAACCGGATCTTAT 
121 A IRS A INN L I VEL I R G T G S Y 
421 AATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCTCTGCCATGGACAGAGCA 
141 N R S S F E S SSG L V W T SAM D R A 
481 CATTACAATATAGTTACTTTCGCCGGCCCTGCAACTTGA 
























NgoMiV (5774) -----'. 
Ncol (5733) 
Figure B3 pLSB2295 TMV based vector provided by LSBC, which contains the NgoMIVI 
Ncol cloning site at the N-terminus of the TMV coat protein. 
(5) pLSB2295 coat protein sequence 
Translation of pLSB2295 cp(1-486) 
Total amino acid number: 161, MW=17639 
Max ORF starts at AA pos l(may be DNA pos 1) for 161 AA(483 bases), 
MW=17639 
1 CCATGGNNGCCGGCTCTTACAGTATCACTACTCCATCTCAGTTCGTGTTCTTGTCATCAGCG 
1 M X A G S Y SIT T P S Q F V F L S S A 
61 TGGGCCGACCCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAA 
21 WAD PIE LIN L C T N A L G N Q F Q 
121 ACACAACAAGCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCA 
41 T Q Q ART V V Q R Q F S E V W K P S P 
181 CAAGTAACTGTTAGGTTCCCTGACAGTGACTTTAAGGTGTACAGGTACAATGCGGTATTA 
61 Q V T V R F P D S D F K V Y R Y N A V L 
241 GACCCGCTAGTCACAGCACTGTTAGGTGCATTCGACACTAGAAATAGAATAATAGAAGTT 
81 D P L V TAL L G A F D T R N R I I E V 
301 GAAAATCAGGCGAACCCCACGACTGCCGAGACGTTAGATGCTACTCGTAGAGTAGACGAC 
101 E N Q A N P T T A E T L D A T R R V D D 
361 GCAACGGTGGCCATAAGGAGCGCGATAAATAATTTAATAGTAGAATTGATCAGAGGAACC 
121 A T V A IRS A INN L I VEL I R G T 
421 GGATCTTATAATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTGGTTTGGACCTCTCCTGCA 
141 G S Y N R S S F E S SSG L V W T SPA 
481 ACTTGA 















Figure B4 pLSB2296 TMV based vector provided by LSBC, which contains the NgoMIVI 
Ncol cloning site at the 60'S loop region of the TMV coat protein. 
(7) pLSB 2296 coat protein sequence 
Translation of 2296 cp(1-504) 
Total amino acid number: 167, MW=18210 
Max ORF starts at AA pos l(may be DNA pos 1) for 167 AA(501 bases), 
MW=18210 
1 ATGTCTTACAGTATCACTACTCCATCTCAGTTCGTGTTCTTGTCATCAGCGTGGGCCGAC 
1 M S Y SIT T P S Q F V F L S SAW A D 
61 CCAATAGAGTTAATTAATTTATGTACTAATGCCTTAGGAAATCAGTTTCAAACACAACAA 
21 PIE LIN L C T N A L G N Q F Q T Q Q 
121 GCTCGAACTGTCGTTCAAAGACAATTCAGTGAGGTGTGGAAACCTTCACCACAAGTAACT 
41 ART V V Q R Q F S E V W K P S P Q V T 
181 GTTAGGTCCCCTGGATCTCCCATGGACAGTGCCGGCCCTTCTGGAGACTTTAAGGTGTAC 
61 V R S P G S P M D S AG PSG D F K V Y 
241 AGGTACAAT GCGGTATTAGACCCGCTAGT CACAGCACTGTTAGGTGCATTCGACACT AGA 
81 R Y N A V L D P L V TAL L G A F D T R 
301 AATAGAATAATAGAAGTT GAAAATCAGGCGAACCCCACGACT GCCGAGACGTTAGATGCT 
101 N R I I EVE N Q A N P T T A E T L D A 
361 ACTCGTAGAGTAGACGACGCAACGGTGGCCATAAGGAGCGCGATAAATAATTTAATAGTA 
121 T R R V D D A T V A IRS A INN L I V 
421 GAATTGATCAGAGGAACCGGATCTTATAATCGGAGCTCTTTCGAGAGCTCTTCTGGTTTG 
141 ELI R G T G S Y N R S S F E S SSG L 
481 GTTTGGACCTCTCCTGCAACTTGA 











All pLSB vectors contained a pUC backbone, which conferred ampicillin 
resistance. All pLSB vectors were prepared for ligation by Neal and NgoMIV 
restriction enzyme digestion (Chapter 2.2.2) followed by Shrimp Alkaline 
Phosphatase treatment (Appendix A(III)) to prevent self-ligation a nd ensure that 
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I. Oligonucleotides used 
Synthetic primer sequences used were synthesized by the Oligonucleotide 
Synthesizing Service of the Department of Molecular and Cell Biology, University 
of Cape Town, Cape Town, South Africa. 
TableC1: Displaying Oligonucleotides used for the PCR assembly of the indicated V3-
epitopes. 
(C) 5'CCGGAAGAGC 5'CGAATAGGAC 5'CGGAAGAGTA 5'CGAATTGGAC 
ATCCGGATCG CAGGACAGAC TTCGAATTGG CAGGACAGGC 
GACCAGGACA ATTCTATGCA ACCAGGACAG ATTCTATACA 
AACATTTTAT 3' ACAGGAGAGA 3' GCATTCTATA 3' AACCACATCA 3' 
(D) 5 ' r.GCCGC.,CGGT 5 ' AGCCGGCT _II.T 
~r:-',:~,:",:,:,~'T' - - ------- _ ..... TATCTCTCCT GATGTGGTTT 











II. peR temperature profiles 
Stage 1 PCR profile: 
20 sec 
I X 10 cycles 
Stage 2 PCR profile: 
20 sec 
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